WO2021109737A1 - 一种含氧杂环化合物、其制备方法及应用 - Google Patents
一种含氧杂环化合物、其制备方法及应用 Download PDFInfo
- Publication number
- WO2021109737A1 WO2021109737A1 PCT/CN2020/122335 CN2020122335W WO2021109737A1 WO 2021109737 A1 WO2021109737 A1 WO 2021109737A1 CN 2020122335 W CN2020122335 W CN 2020122335W WO 2021109737 A1 WO2021109737 A1 WO 2021109737A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- independently
- substituted
- heteroatoms
- halogen
- Prior art date
Links
- 0 CN1[C@](C*c2nc(CC(c3cccc4cccc(Cl)c34)OC3)c3c(N(CC3)C[C@](CC#N)N3C(C(F)=C)=O)n2)CCC1 Chemical compound CN1[C@](C*c2nc(CC(c3cccc4cccc(Cl)c34)OC3)c3c(N(CC3)C[C@](CC#N)N3C(C(F)=C)=O)n2)CCC1 0.000 description 7
- DOUDKPJUSUTSCJ-SYDXZMBCSA-N CN1[C@@H](COc2nc(CC(c3cccc4cccc(Cl)c34)OC3)c3c(N(CC3)C[C@H](CC#N)N3C(C(F)=C)=O)n2)CCC1 Chemical compound CN1[C@@H](COc2nc(CC(c3cccc4cccc(Cl)c34)OC3)c3c(N(CC3)C[C@H](CC#N)N3C(C(F)=C)=O)n2)CCC1 DOUDKPJUSUTSCJ-SYDXZMBCSA-N 0.000 description 2
- QHAKQJHNFQRVOF-QGGGIAGFSA-N CN1[C@H](COc2nc(N(CC3)C[C@H](CC#N)N3C(C(F)=C)=O)c(COC(C3)c4c(C(F)(F)F)cccc4)c3n2)CCC1 Chemical compound CN1[C@H](COc2nc(N(CC3)C[C@H](CC#N)N3C(C(F)=C)=O)c(COC(C3)c4c(C(F)(F)F)cccc4)c3n2)CCC1 QHAKQJHNFQRVOF-QGGGIAGFSA-N 0.000 description 2
- YHMSQKZZNGUFFL-FOCHENRBSA-N Cc1c(c(C(C2)OCc(c(N3C[C@H](CC#N)NCC3)n3)c2nc3OC[C@@H]2N(C)CCC2)ccc2)c2ccc1 Chemical compound Cc1c(c(C(C2)OCc(c(N3C[C@H](CC#N)NCC3)n3)c2nc3OC[C@@H]2N(C)CCC2)ccc2)c2ccc1 YHMSQKZZNGUFFL-FOCHENRBSA-N 0.000 description 2
- ZXUVXVHZHFVTAI-HYDRXZQLSA-N C/C=C/C(N(CC1)[C@@H](CC#N)CN1c1nc(OC[C@H]2N(C)CCC2)nc(C2)c1COC2c1cccc2cccc(C)c12)=O Chemical compound C/C=C/C(N(CC1)[C@@H](CC#N)CN1c1nc(OC[C@H]2N(C)CCC2)nc(C2)c1COC2c1cccc2cccc(C)c12)=O ZXUVXVHZHFVTAI-HYDRXZQLSA-N 0.000 description 1
- AZBLOTMLMBRMEG-ONEGZZNKSA-N CC(/C=C/C(CCNC)=O)=O Chemical compound CC(/C=C/C(CCNC)=O)=O AZBLOTMLMBRMEG-ONEGZZNKSA-N 0.000 description 1
- NVNADPKWPBIGCS-NSCUHMNNSA-N CC(/C=C/C(N)=O)=O Chemical compound CC(/C=C/C(N)=O)=O NVNADPKWPBIGCS-NSCUHMNNSA-N 0.000 description 1
- IEJCPROEFZVTSN-CYFREDJKSA-N CC(C)(C)OC(N(CC1)[C@@H](CC#N)CN1c1nc(S(C)(=O)=O)nc(C2)c1CO[C@@H]2c1cccc2cccc(Cl)c12)=O Chemical compound CC(C)(C)OC(N(CC1)[C@@H](CC#N)CN1c1nc(S(C)(=O)=O)nc(C2)c1CO[C@@H]2c1cccc2cccc(Cl)c12)=O IEJCPROEFZVTSN-CYFREDJKSA-N 0.000 description 1
- NAVLQXRRAYMUAV-UHFFFAOYSA-N CC(C)C(CC1)=CCN1NC Chemical compound CC(C)C(CC1)=CCN1NC NAVLQXRRAYMUAV-UHFFFAOYSA-N 0.000 description 1
- MITNQMBIBXWZTA-UHFFFAOYSA-N CC(C)N(CC1)CCN1NC Chemical compound CC(C)N(CC1)CCN1NC MITNQMBIBXWZTA-UHFFFAOYSA-N 0.000 description 1
- ACRGRODPDITZPN-MRCLHIKOSA-N CC(C1)[C@H]1/C=C(\C(O)=O)/F Chemical compound CC(C1)[C@H]1/C=C(\C(O)=O)/F ACRGRODPDITZPN-MRCLHIKOSA-N 0.000 description 1
- NCXUNZWLEYGQAH-UHFFFAOYSA-N CC(CN(C)C)O Chemical compound CC(CN(C)C)O NCXUNZWLEYGQAH-UHFFFAOYSA-N 0.000 description 1
- LTUFHVOXGITHBP-HLTVDCFTSA-N CC(CN(C)C)Oc1nc(CC(c2cccc3cccc(C)c23)OC2)c2c(N2C[C@H](CC#N)NCC2)n1 Chemical compound CC(CN(C)C)Oc1nc(CC(c2cccc3cccc(C)c23)OC2)c2c(N2C[C@H](CC#N)NCC2)n1 LTUFHVOXGITHBP-HLTVDCFTSA-N 0.000 description 1
- JXAYJIOJRCHVED-UBSNYXNISA-N CC(CN(C)C)Oc1nc(C[C@@H](c2cccc3cccc(Cl)c23)OC2)c2c(N(CC2)C[C@H](CC#N)N2C(C=C)=O)n1 Chemical compound CC(CN(C)C)Oc1nc(C[C@@H](c2cccc3cccc(Cl)c23)OC2)c2c(N(CC2)C[C@H](CC#N)N2C(C=C)=O)n1 JXAYJIOJRCHVED-UBSNYXNISA-N 0.000 description 1
- BNMDLNMQTWAUGF-ZZGCQTQBSA-N CC(CN(C)C)Oc1nc(C[C@@H](c2cccc3cccc(Cl)c23)OC2)c2c(N(CC2)C[C@H](CC#N)N2C(OC(C)(C)C)=O)n1 Chemical compound CC(CN(C)C)Oc1nc(C[C@@H](c2cccc3cccc(Cl)c23)OC2)c2c(N(CC2)C[C@H](CC#N)N2C(OC(C)(C)C)=O)n1 BNMDLNMQTWAUGF-ZZGCQTQBSA-N 0.000 description 1
- NPKKPTBFFNQOIG-ZGCXKRIGSA-N CC(CN(C)C)Oc1nc(C[C@@H](c2cccc3cccc(Cl)c23)OC2)c2c(N2C[C@H](CC#N)NCC2)n1 Chemical compound CC(CN(C)C)Oc1nc(C[C@@H](c2cccc3cccc(Cl)c23)OC2)c2c(N2C[C@H](CC#N)NCC2)n1 NPKKPTBFFNQOIG-ZGCXKRIGSA-N 0.000 description 1
- HJOJXHUECIGVFT-QHNHZXLYSA-N CCCN[C@@H](CC#N)CNc1nc(OCCN(C)Cc2cc(cccc3C)c3c(C(C3)OCc(c(N4C[C@H](CC#N)NCC4)n4)c3nc4OCCN(CC)CC)c2)nc(C2)c1COC2c1cccc2cccc(C)c12 Chemical compound CCCN[C@@H](CC#N)CNc1nc(OCCN(C)Cc2cc(cccc3C)c3c(C(C3)OCc(c(N4C[C@H](CC#N)NCC4)n4)c3nc4OCCN(CC)CC)c2)nc(C2)c1COC2c1cccc2cccc(C)c12 HJOJXHUECIGVFT-QHNHZXLYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N CCN(CC)CCO Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- ISFROTXPDSRZKP-GMMLNUAGSA-N CCN(CC)CCOc1nc(CC(c2cccc3cccc(C)c23)OC2)c2c(N(CC2)C[C@H](CC#N)N2C(C=C)=O)n1 Chemical compound CCN(CC)CCOc1nc(CC(c2cccc3cccc(C)c23)OC2)c2c(N(CC2)C[C@H](CC#N)N2C(C=C)=O)n1 ISFROTXPDSRZKP-GMMLNUAGSA-N 0.000 description 1
- AEAJZVAKQMDAIU-DCCUJTHKSA-N CCN(CCOc1nc(CC(c2cccc3cccc(C)c23)OC2)c2c(N2C[C@H](CC#N)NCC2)n1)C=C Chemical compound CCN(CCOc1nc(CC(c2cccc3cccc(C)c23)OC2)c2c(N2C[C@H](CC#N)NCC2)n1)C=C AEAJZVAKQMDAIU-DCCUJTHKSA-N 0.000 description 1
- UVHWAXJYNRDIKO-ONEGZZNKSA-N CCOC(/C=C/CN1CCOCC1)=O Chemical compound CCOC(/C=C/CN1CCOCC1)=O UVHWAXJYNRDIKO-ONEGZZNKSA-N 0.000 description 1
- YKLXAOVJOYCMFL-GMMLNUAGSA-N CCc(c(N1C[C@H](CC#N)N(C)CC1)n1)c(CC(c2cccc3cccc(C)c23)O)nc1OCCN(CC)CC Chemical compound CCc(c(N1C[C@H](CC#N)N(C)CC1)n1)c(CC(c2cccc3cccc(C)c23)O)nc1OCCN(CC)CC YKLXAOVJOYCMFL-GMMLNUAGSA-N 0.000 description 1
- JTAYXEIPUKLUOX-ONEGZZNKSA-N CN(C)C/C=C/C=O Chemical compound CN(C)C/C=C/C=O JTAYXEIPUKLUOX-ONEGZZNKSA-N 0.000 description 1
- OQFWAXWPPRTXML-VVESCEMWSA-N CN1C(COc2nc(CC(c3ccccc3C(F)(F)F)OC3)c3c(N3C[C@H](CC#N)NCC3)n2)CCC1 Chemical compound CN1C(COc2nc(CC(c3ccccc3C(F)(F)F)OC3)c3c(N3C[C@H](CC#N)NCC3)n2)CCC1 OQFWAXWPPRTXML-VVESCEMWSA-N 0.000 description 1
- VCOJPHPOVDIRJK-ZCFIWIBFSA-N CN1[C@@H](CO)CCC1 Chemical compound CN1[C@@H](CO)CCC1 VCOJPHPOVDIRJK-ZCFIWIBFSA-N 0.000 description 1
- VYSZDXSQJBGUKJ-YEOOOGFDSA-N CN1[C@@H](COc2nc(CC(c3cccc4cccc(Cl)c34)OC3)c3c(N(CC3)C[C@H](CC#N)N3OC(c3ccccc3)=O)n2)CCC1 Chemical compound CN1[C@@H](COc2nc(CC(c3cccc4cccc(Cl)c34)OC3)c3c(N(CC3)C[C@H](CC#N)N3OC(c3ccccc3)=O)n2)CCC1 VYSZDXSQJBGUKJ-YEOOOGFDSA-N 0.000 description 1
- SEFBCGPLDDHXBF-QGGGIAGFSA-N CN1[C@H](COc2nc(CC(c3ccccc3Cl)OC3)c3c(N(CC3)C[C@H](CC#N)N3C(C(F)=C)=O)n2)CCC1 Chemical compound CN1[C@H](COc2nc(CC(c3ccccc3Cl)OC3)c3c(N(CC3)C[C@H](CC#N)N3C(C(F)=C)=O)n2)CCC1 SEFBCGPLDDHXBF-QGGGIAGFSA-N 0.000 description 1
- CGBVYWFLQOPUDL-JOHXPNBHSA-N CN1[C@H](COc2nc(CC(c3ccccc3Cl)OC3)c3c(N3C[C@H](CC#N)NCC3)n2)CCC1 Chemical compound CN1[C@H](COc2nc(CC(c3ccccc3Cl)OC3)c3c(N3C[C@H](CC#N)NCC3)n2)CCC1 CGBVYWFLQOPUDL-JOHXPNBHSA-N 0.000 description 1
- SIEUGROMIDEQMX-WOVHNISZSA-N CN1[C@H](COc2nc(C[C@@H](c3cccc4cccc(Cl)c34)OC3)c3c(N3C[C@H](CC#N)NCC3)n2)CCC1 Chemical compound CN1[C@H](COc2nc(C[C@@H](c3cccc4cccc(Cl)c34)OC3)c3c(N3C[C@H](CC#N)NCC3)n2)CCC1 SIEUGROMIDEQMX-WOVHNISZSA-N 0.000 description 1
- YXSCQRLUQFPPOJ-SFTDATJTSA-N CN1[C@H](COc2nc(N(CC3)C[C@H](CC#N)N3C(C=C)=O)c(CCN(C3)c4ccccc4C(F)(F)F)c3n2)CCC1 Chemical compound CN1[C@H](COc2nc(N(CC3)C[C@H](CC#N)N3C(C=C)=O)c(CCN(C3)c4ccccc4C(F)(F)F)c3n2)CCC1 YXSCQRLUQFPPOJ-SFTDATJTSA-N 0.000 description 1
- GNDDNPLOIDNSCL-NSCUHMNNSA-N CNC(/C=C/CN1CCOCC1)=O Chemical compound CNC(/C=C/CN1CCOCC1)=O GNDDNPLOIDNSCL-NSCUHMNNSA-N 0.000 description 1
- GJGCNYIFSDUOTG-UHFFFAOYSA-N COC(C(C(C1)=O)=COC1c1ccccc1Cl)=O Chemical compound COC(C(C(C1)=O)=COC1c1ccccc1Cl)=O GJGCNYIFSDUOTG-UHFFFAOYSA-N 0.000 description 1
- NASGKPLUTASRHX-YMQLSTQVSA-N CSc1nc(N(CC2)C[C@H](CC#N)N2OC(c2ccccc2)=O)c(COC(C2)c3cccc4cccc(Cl)c34)c2n1 Chemical compound CSc1nc(N(CC2)C[C@H](CC#N)N2OC(c2ccccc2)=O)c(COC(C2)c3cccc4cccc(Cl)c34)c2n1 NASGKPLUTASRHX-YMQLSTQVSA-N 0.000 description 1
- MDTXURGIFAJHQT-SNSLUYJLSA-N C[C@@H](C(N(CC1)[C@@H](CC#N)CN1c1nc(OC[C@H]2N(C)CCC2)nc(C2)c1COC2c1cccc2cccc(Cl)c12)=O)F Chemical compound C[C@@H](C(N(CC1)[C@@H](CC#N)CN1c1nc(OC[C@H]2N(C)CCC2)nc(C2)c1COC2c1cccc2cccc(Cl)c12)=O)F MDTXURGIFAJHQT-SNSLUYJLSA-N 0.000 description 1
- JZLRYUASPYLXLL-MBFPYBOQSA-N C[C@@H](CC(N)=O)CN(CCN)c1nc(OC[C@H](C2)N(C)CC2c(cc2[C@H](C3)OCc(c(N4C[C@@H](CC#N)NCC4)n4)c3nc4OC[C@H]3N(C)CCC3)cc3c2c(Cl)ccc3)nc(C2)c1CO[C@@H]2c1c2c(Cl)cccc2c(C2CN(C)[C@H](COc3nc(CC(c(c4ccc5)cncc4c5N(C)CC(C)Oc4nc(C[C@@H](c5cccc6cccc(C)c56)OC5)c5c(N5C[C@H](CC#N)NCC5)n4)OC4)c4c(N4C[C@H](CC#N)NCC4)n3)C2)cc1 Chemical compound C[C@@H](CC(N)=O)CN(CCN)c1nc(OC[C@H](C2)N(C)CC2c(cc2[C@H](C3)OCc(c(N4C[C@@H](CC#N)NCC4)n4)c3nc4OC[C@H]3N(C)CCC3)cc3c2c(Cl)ccc3)nc(C2)c1CO[C@@H]2c1c2c(Cl)cccc2c(C2CN(C)[C@H](COc3nc(CC(c(c4ccc5)cncc4c5N(C)CC(C)Oc4nc(C[C@@H](c5cccc6cccc(C)c56)OC5)c5c(N5C[C@H](CC#N)NCC5)n4)OC4)c4c(N4C[C@H](CC#N)NCC4)n3)C2)cc1 JZLRYUASPYLXLL-MBFPYBOQSA-N 0.000 description 1
- QSWRBNLLOHIXDL-UHFFFAOYSA-N Cc1c(C(CC(CC(OC)=O)=O)O)cccc1 Chemical compound Cc1c(C(CC(CC(OC)=O)=O)O)cccc1 QSWRBNLLOHIXDL-UHFFFAOYSA-N 0.000 description 1
- SWCBOWYWYRVZFM-CHQVSRGASA-N Cc1c(c(C(C2)OCc(c(C3=CCNCC3)n3)c2nc3OC[C@H]2N(C)CCC2)ccc2)c2ccc1 Chemical compound Cc1c(c(C(C2)OCc(c(C3=CCNCC3)n3)c2nc3OC[C@H]2N(C)CCC2)ccc2)c2ccc1 SWCBOWYWYRVZFM-CHQVSRGASA-N 0.000 description 1
- QVWVEZRRNWDMHX-RJPKHYMBSA-N Cc1c(c(C(C2)OCc(c(N(CC3)C[C@H](CC#N)N3C(/C=C/CN3CCOCC3)=O)n3)c2nc3OC[C@H]2N(C)CCC2)ccc2)c2ccc1 Chemical compound Cc1c(c(C(C2)OCc(c(N(CC3)C[C@H](CC#N)N3C(/C=C/CN3CCOCC3)=O)n3)c2nc3OC[C@H]2N(C)CCC2)ccc2)c2ccc1 QVWVEZRRNWDMHX-RJPKHYMBSA-N 0.000 description 1
- DYOXTIKCYZCWMB-KOKAMKNVSA-N Cc1c(c(C(C2)OCc(c(N(CC3)C[C@H](CC#N)N3C(C=C)=O)n3)c2nc3OCC2N(C)CCC2)ccc2)c2ccc1 Chemical compound Cc1c(c(C(C2)OCc(c(N(CC3)C[C@H](CC#N)N3C(C=C)=O)n3)c2nc3OCC2N(C)CCC2)ccc2)c2ccc1 DYOXTIKCYZCWMB-KOKAMKNVSA-N 0.000 description 1
- NNGPCPKWOGRHFO-DCCUJTHKSA-N Cc1c(c(C(C2)OCc(c(N(CC3)C[C@H](CC#N)N3C(C=C)=O)n3)c2nc3OCCN(C)C)ccc2)c2ccc1 Chemical compound Cc1c(c(C(C2)OCc(c(N(CC3)C[C@H](CC#N)N3C(C=C)=O)n3)c2nc3OCCN(C)C)ccc2)c2ccc1 NNGPCPKWOGRHFO-DCCUJTHKSA-N 0.000 description 1
- MXKMJPDXTKTTEV-GQRJPBKSSA-N Cc1c(c(C(C2)OCc(c(N(CC3)C[C@H](CC#N)N3OC(c3ccccc3)=O)n3)c2nc3OCCN(C)c2c(cccc3C)c3c(C(C3)OCc(c(N4C[C@H](CC#N)NCC4)n4)c3nc4O)cc2)ccc2)c2ccc1 Chemical compound Cc1c(c(C(C2)OCc(c(N(CC3)C[C@H](CC#N)N3OC(c3ccccc3)=O)n3)c2nc3OCCN(C)c2c(cccc3C)c3c(C(C3)OCc(c(N4C[C@H](CC#N)NCC4)n4)c3nc4O)cc2)ccc2)c2ccc1 MXKMJPDXTKTTEV-GQRJPBKSSA-N 0.000 description 1
- QTCDEZJOMXZQAU-DCCUJTHKSA-N Cc1c(c(C(C2)OCc(c(N3CCC4(CNC4)CC3)n3)c2nc3OC[C@H]2N(C)CCC2)ccc2)c2ccc1 Chemical compound Cc1c(c(C(C2)OCc(c(N3CCC4(CNC4)CC3)n3)c2nc3OC[C@H]2N(C)CCC2)ccc2)c2ccc1 QTCDEZJOMXZQAU-DCCUJTHKSA-N 0.000 description 1
- GEABOLPAZWLWFO-CHQVSRGASA-N Cc1c(c(C(C2)OCc(c(N3C[C@H](CC#N)NCC3)n3)c2nc3OCCCN(C)C)ccc2)c2ccc1 Chemical compound Cc1c(c(C(C2)OCc(c(N3C[C@H](CC#N)NCC3)n3)c2nc3OCCCN(C)C)ccc2)c2ccc1 GEABOLPAZWLWFO-CHQVSRGASA-N 0.000 description 1
- FIPBVTKMKZQJRE-PFXBLUCKSA-N Cc1c(c(C(C2)OCc(c(N3C[C@H](CC#N)NCC3)n3)c2nc3OC[C@H](C2)N(C)CC2(F)F)ccc2)c2ccc1 Chemical compound Cc1c(c(C(C2)OCc(c(N3C[C@H](CC#N)NCC3)n3)c2nc3OC[C@H](C2)N(C)CC2(F)F)ccc2)c2ccc1 FIPBVTKMKZQJRE-PFXBLUCKSA-N 0.000 description 1
- YHMSQKZZNGUFFL-ZDNIZFJCSA-N Cc1c(c(C(C2)OCc(c(N3C[C@H](CC#N)NCC3)n3)c2nc3OC[C@H]2N(C)CCC2)ccc2)c2ccc1 Chemical compound Cc1c(c(C(C2)OCc(c(N3C[C@H](CC#N)NCC3)n3)c2nc3OC[C@H]2N(C)CCC2)ccc2)c2ccc1 YHMSQKZZNGUFFL-ZDNIZFJCSA-N 0.000 description 1
- BFKVTXUQWXFVOL-CHQVSRGASA-N Cc1cccc2c1c(C(C1)OCc(c(C3CCNCC3)n3)c1nc3OC[C@H]1N(C)CCC1)ccc2 Chemical compound Cc1cccc2c1c(C(C1)OCc(c(C3CCNCC3)n3)c1nc3OC[C@H]1N(C)CCC1)ccc2 BFKVTXUQWXFVOL-CHQVSRGASA-N 0.000 description 1
- HBMLMADOJDCYHI-CXBRBUDWSA-N Cc1cccc2cccc(C(C3)OCc(c(N(CC4)C[C@H](CC#N)N4C(C(F)=C)=O)n4)c3nc4OC[C@H]3N(C)CCC3)c12 Chemical compound Cc1cccc2cccc(C(C3)OCc(c(N(CC4)C[C@H](CC#N)N4C(C(F)=C)=O)n4)c3nc4OC[C@H]3N(C)CCC3)c12 HBMLMADOJDCYHI-CXBRBUDWSA-N 0.000 description 1
- BYIHNTNJLHANBG-UHFFFAOYSA-N Cc1ccccc1C(C1)OCC(C(OC)=O)C1=O Chemical compound Cc1ccccc1C(C1)OCC(C(OC)=O)C1=O BYIHNTNJLHANBG-UHFFFAOYSA-N 0.000 description 1
- RVXOQCCQDSMMFB-ZLTNKZLJSA-N Cc1ccccc1C(C1)OCc(c(N2C[C@H](CC#N)N(C)CC2)n2)c1nc2OC[C@H]1N(C)CCC1 Chemical compound Cc1ccccc1C(C1)OCc(c(N2C[C@H](CC#N)N(C)CC2)n2)c1nc2OC[C@H]1N(C)CCC1 RVXOQCCQDSMMFB-ZLTNKZLJSA-N 0.000 description 1
- MSTWVBLYLGXEOX-ZRENRBBTSA-N Cc1ccccc1C(C1)OCc(c(N2C[C@H](CC#N)NCC2)n2)c1nc2OC[C@H]1N(C)CCC1 Chemical compound Cc1ccccc1C(C1)OCc(c(N2C[C@H](CC#N)NCC2)n2)c1nc2OC[C@H]1N(C)CCC1 MSTWVBLYLGXEOX-ZRENRBBTSA-N 0.000 description 1
- PPAVBMAYMMQXOF-UHFFFAOYSA-N Cc1ccccc1C(C1)OCc(c(O)n2)c1nc2SC Chemical compound Cc1ccccc1C(C1)OCc(c(O)n2)c1nc2SC PPAVBMAYMMQXOF-UHFFFAOYSA-N 0.000 description 1
- BTFQKIATRPGRBS-UHFFFAOYSA-N Cc1ccccc1C=O Chemical compound Cc1ccccc1C=O BTFQKIATRPGRBS-UHFFFAOYSA-N 0.000 description 1
- BGXQWNCREDOPDU-UHFFFAOYSA-N IC(CC1)=CCN1I Chemical compound IC(CC1)=CCN1I BGXQWNCREDOPDU-UHFFFAOYSA-N 0.000 description 1
- NQBJCXRWOOUGQF-UHFFFAOYSA-N IN(C1)CC1(CC1)CCN1I Chemical compound IN(C1)CC1(CC1)CCN1I NQBJCXRWOOUGQF-UHFFFAOYSA-N 0.000 description 1
- KSUQSWRQOSUKKK-UHFFFAOYSA-N IN(CC1)CCN1I Chemical compound IN(CC1)CCN1I KSUQSWRQOSUKKK-UHFFFAOYSA-N 0.000 description 1
- UHQOGVXXLNSLGA-UHFFFAOYSA-N NN(C1)CC1(CC1)CCN1I Chemical compound NN(C1)CC1(CC1)CCN1I UHQOGVXXLNSLGA-UHFFFAOYSA-N 0.000 description 1
- CRLBJPREWTVTBA-JTQLQIEISA-N OC[C@H]1N(CCC2CC2)CCC1 Chemical compound OC[C@H]1N(CCC2CC2)CCC1 CRLBJPREWTVTBA-JTQLQIEISA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Definitions
- the invention relates to an oxygen-containing heterocyclic compound, its preparation method and application.
- Ras Ras (Rat sarcoma viral oncogene, murine sarcoma virus oncogene) was first discovered in rat sarcoma.
- the mammalian ras gene family has three members, namely H-ras, K-ras, and N-ras. Among them, the fourth exon of K-ras has two variants, A and B.
- Ras genes are widely present in various eukaryotes, such as mammals, fruit flies, fungi, nematodes and yeast, and are expressed to varying degrees in different tissues.
- H-Ras is mainly expressed in skin and skeletal muscle
- K-Ras is mainly It is expressed in the colon and thymus
- N-Ras is highly expressed in the testis.
- Ras protein regulates signal transduction by combining with GTP/GDP, and then regulates cell proliferation, differentiation, aging and apoptosis and other life processes.
- Ras mutation is closely related to the occurrence and development of tumors. Ras gene is mutated in more than 30% of human tumors and is considered to be one of the most powerful cancer drivers. Ras proto-oncogene mutations are mainly carried out through point mutations. More than 150 different Ras point mutations have been found, among which the mutations with glycine at positions 12 and 13 and glutamine at 61 are the most common.
- K-Ras G12C mutants They identified a new binding pocket located below the molecular switch II region from the K-Ras G12C mutant. These inhibitors bind to the allosteric pocket and form a covalent bond with nearby Cys12, thereby selectively inhibiting K-Ras Activation of G12C.
- Other researchers have reported KRAS inhibitors with cellular activity (Science, 2016, 351, 604-608). There are currently drugs in the clinical development stage. Amgen's compound AMG510 began clinical trials in 2018 and is the first small molecule inhibitor that directly targets KRAS to enter the clinic.
- the technical problem to be solved by the present invention is that there is no effective drug as a Ras inhibitor for clinical treatment in the prior art. For this reason, the present invention provides an oxygen-containing heterocyclic compound, a preparation method and application thereof. Cyclic compounds are expected to treat and/or prevent various diseases mediated by Ras.
- the present invention solves the above technical problems through the following technical solutions.
- the present invention provides an oxygen-containing heterocyclic compound represented by formula I, its pharmaceutically acceptable salt, its stereoisomer, its tautomer or its isotopic compound:
- R 1 is a C 6-20 aryl group, "a 5-12 membered heteroaryl group containing 1-4 heteroatoms, and one or more of O, S and N", and one or more A C 6-20 aryl group substituted by R 1-6 , or a C 6-20 aryl group substituted by one or more R 1-7 "containing 1-4 heteroatoms, the heteroatoms are one or more of O, S and N Species of 5-12 membered heteroaryl";
- R 65 , R 65-2 , R 63 , R 63-2 , R 64 , R 64-2 , R 66 , R 66-2 , R 69 , R 69-2 , R 610 and R 610-2 are independently Hydrogen or C 1-6 alkyl;
- n 0, 1 or 2;
- R 5 is independently C 1-6 alkyl
- R 3 is -OR 31 , -SR 32 or -NR 33 R 34 ;
- R 31 , R 32 and R 34 are independently C 1-6 alkyl substituted by one or more R 31-1 ;
- R 33 is independently H, C 1-6 alkyl, or by one or more R 31-1 substituted C 1-6 alkyl;
- R d , R d1 , Re1 , Re2 , Re3 and Re4 are independently hydrogen, C 1-6 alkyl, C 3-10 cycloalkyl, "containing 1-3 heteroatoms, and the heteroatom is O And one or more 4-10 membered heterocycloalkyl groups in N", or C 1-6 alkyl substituted by one or more R 1-8-2;
- R e5 , R e6 , R e7 , R e8 , R e9 , R e10 , R e11 , R e12 , R e13 and R e14 are independently hydrogen or C 1-6 alkyl;
- Ring Y is a 4-12 membered heterocyclic ring containing 1-4 N atoms; the heterocyclic ring is a saturated heterocyclic ring or a partially saturated heterocyclic ring; the heterocyclic ring is a monocyclic ring, a bridged ring or a spiro ring;
- G is N, C or CH
- n 0, 1, 2 or 3;
- R 4d , R 4e , R 4f , R 4i and R 4j are independently hydrogen or C 1-6 alkyl;
- R 4a , R 4b and R 4c are independently hydrogen or C 1-6 alkyl
- R a is independently hydrogen, deuterium, halogen or C 1-6 alkyl
- R b-1 is independently halogen, hydroxyl, C 1-6 alkoxy, or -NR 10j R 10k ;
- R 10j and R 10k are independently hydrogen or C 1-6 alkyl, or, R 10j , R 10k and the N connected to them together form "containing 1-3 heteroatoms, and the heteroatoms are one of O and N One or more 4-10 membered heterocycloalkyl".
- R 1 is a C 6-20 aryl group, "a 5-12 membered heteroaryl group containing 1-4 heteroatoms, and one or more of O, S and N", and one or more A C 6-20 aryl group substituted by R 1-6 , or a C 6-20 aryl group substituted by one or more R 1-7 "containing 1-4 heteroatoms, the heteroatoms are one or more of O, S and N Species of 5-12 membered heteroaryl";
- R 65 , R 65-2 , R 63 , R 63-2 , R 64 , R 64-2 , R 66 , R 66-2 , R 69 , R 69-2 , R 610 and R 610-2 are independently Hydrogen or C 1-6 alkyl;
- n 0, 1 or 2;
- R 5 is independently C 1-6 alkyl
- R 3 is -OR 31 , -SR 32 or -NR 33 R 34 ;
- R 31 , R 32 , R 33 and R 34 are independently C 1-6 alkyl substituted with one or more R 31-1;
- R d , R d1 , Re1 , Re2 , Re3 and Re4 are independently hydrogen, C 1-6 alkyl, C 3-10 cycloalkyl, "containing 1-3 heteroatoms, and the heteroatom is O And one or more 4-10 membered heterocycloalkyl groups in N", or C 1-6 alkyl substituted by one or more R 1-8-2;
- R e5 , R e6 , R e7 , R e8 , R e9 , R e10 , R e11 , R e12 , R e13 and R e14 are independently hydrogen or C 1-6 alkyl;
- Ring Y is a 4-12 membered heterocyclic ring containing 1-4 N atoms; the heterocyclic ring is a saturated heterocyclic ring or a partially saturated heterocyclic ring; the heterocyclic ring is a monocyclic ring, a bridged ring or a spiro ring;
- G is N, C or CH
- n 0, 1, 2 or 3;
- R 4d , R 4e , R 4f , R 4i and R 4j are independently hydrogen or C 1-6 alkyl;
- R 4a , R 4b and R 4c are independently hydrogen or C 1-6 alkyl
- R a is independently hydrogen, deuterium, halogen or C 1-6 alkyl
- R b and R f are independently hydrogen, deuterium, C 1-6 alkyl, or C 1-6 alkyl substituted with one or more R b-1;
- R b-1 is independently halogen, hydroxyl, C 1-6 alkoxy, or -NR 10j R 10k ;
- R 10j and R 10k are independently hydrogen or C 1-6 alkyl, or, R 10j , R 10k and the N connected to them together form "containing 1-3 heteroatoms, and the heteroatoms are one of O and N One or more 4-10 membered heterocycloalkyl".
- R 1 is a C 6-20 aryl group, "a 5-12 membered heteroaryl group containing 1-4 heteroatoms, and one or more of O, S, and N", and one or more R 1-6 substituted C 6-20 aryl, or, substituted by one or more R 1-7 "containing 1-4 heteroatoms, heteroatoms are one or more of O, S and N 5-12 membered heteroaryl";
- R 1-6 and R 1-7 are independently halogen, hydroxy, C 1-6 alkyl, C 1-6 alkoxy, C 3-10 cycloalkyl, substituted by one or more R 1-6-1 A substituted C 1-6 alkyl group or a C 1-6 alkoxy group substituted with one or more R 1-6-2 ; R 1-6-1 and R 1-6-2 are independently halogen.
- R 1 is a C 6-20 aryl group, a "5-12 membered heteroaryl group containing 1-4 heteroatoms, and one or more of O, S and N", and one or more R 1-6 substituted C 6-20 aryl, or, substituted by one or more R 1-7 "containing 1-4 heteroatoms, heteroatoms are one or more of O, S and N 5-12 membered heteroaryl group"; for example, C 6-20 aryl group, "5-12 membered heteroaryl group containing 1-4 heteroatoms, and heteroatoms are one or more of O, S and N" , Or, C 6-20 aryl substituted with one or more R 1-6;
- R 1-6 and R 1-7 are independently halogen, C 1-6 alkyl, or C 1-6 alkyl substituted with one or more R 1-6-1;
- R 1-6-1 is independently halogen.
- R 1 is a C 6-20 aryl group, or a C 6-20 aryl group substituted by one or more R 1-6;
- R 1-6 is independently halogen, C 1-6 alkyl, or C 1-6 alkyl substituted with one or more R 1-6-1;
- R 1-6-1 is independently halogen.
- R 3 is -OR 31 , -SR 32 or -NR 33 R 34 ;
- R 31 , R 32 and R 34 are independently C 1-6 alkyl substituted by one or more R 31-1 ;
- R 33 is independently H, C 1-6 alkyl, or by one or more R 31-1 substituted C 1-6 alkyl;
- R 31-1 is independently a "5-7 membered heterocycloalkyl containing 1 to 3 heteroatoms and one or more of O and N" substituted by one or more R d15, or , -NR e1 R e2 ;
- R d15 is independently C 1-6 alkyl or halogen
- R e1 and R e2 are independently C 1-6 alkyl.
- R 3 is -SR 32 ;
- R 32 is C 1-6 alkyl substituted by one or more R 31-1;
- R 31-1 is independently -NR e1 R e2 ;
- R e1 and R e2 are independently C 1-6 alkyl.
- R 3 is -OR 31 or -NR 33 R 34 ;
- R 31 , R 33 and R 34 are independently C 1-6 alkyl substituted with one or more R 31-1;
- R 31-1 is independently a "5-7 membered heterocycloalkyl group containing 1-3 heteroatoms and one or more of O and N" substituted by one or more R d15, or , -NR e1 R e2 ;
- R 1-8-1 is independently halogen;
- R e5 , R e6 , R e7 and R e8 are independently hydrogen or C 1-6 alkyl;
- R e1 and R e2 are independently C 1-6 alkyl.
- R 3 is -NR 33 R 34 ;
- R 34 is independently substituted with one or more R 31-1 substituted with C 1-6 alkyl;
- R 33 is independently H, C 1-6 alkyl or with one or more R 31- 1-substituted C 1 -6 alkyl; such as H or C 1-6 alkyl;
- R 31-1 is independently a "5-7 membered heterocycloalkyl containing 1 to 3 heteroatoms and one or more of O and N" substituted by one or more R d15, or , -NR e1 R e2 ;
- R d15 is independently C 1-6 alkyl
- R e1 and R e2 are independently C 1-6 alkyl.
- R 3 is -OR 31 or -NR 33 R 34 ;
- R 31 and R 34 are independently C 1-6 alkyl substituted by one or more R 31-1 ;
- R 33 are independently H, C 1-6 alkyl or substituted by one or more R 31-1 ⁇ C 1-6 alkyl; for example, H or C 1-6 alkyl;
- R 31-1 is independently a "5-7 membered heterocycloalkyl containing 1 to 3 heteroatoms and one or more of O and N" substituted by one or more R d15, or , -NR e1 R e2 ;
- R d15 is independently C 1-6 alkyl or halogen
- R e1 and R e2 are independently C 1-6 alkyl.
- R 3 is -OR 31 or -NR 33 R 34 ;
- R 31 , R 33 and R 34 are independently C 1-6 alkyl substituted with one or more R 31-1;
- R 31-1 is independently a "5-7 membered heterocycloalkyl containing 1 to 3 heteroatoms and one or more of O and N" substituted by one or more R d15, or , -NR e1 R e2 ;
- R d15 is independently C 1-6 alkyl or halogen
- R e1 and R e2 are independently C 1-6 alkyl.
- R 3 is -OR 31 or -NR 33 R 34 ;
- R 31 , R 33 and R 34 are independently C 1-6 alkyl substituted with one or more R 31-1;
- R 31-1 is independently a "5-7 membered heterocycloalkyl containing 1 to 3 heteroatoms and one or more of O and N" substituted by one or more R d15, or , -NR e1 R e2 ;
- R e1 , R e2 and R d15 are independently C 1-6 alkyl.
- Ring Y is a 4-12 membered heterocyclic ring containing 1-4 N atoms; the heterocyclic ring is a saturated heterocyclic ring or a partially saturated heterocyclic ring; the heterocyclic ring is a monocyclic or spiro ring; for example, a monocyclic ring;
- G is N, C or CH.
- Ring Y is a 4-12 membered heterocyclic ring containing 1-4 N atoms; the heterocyclic ring is a saturated heterocyclic ring or a partially saturated heterocyclic ring; the heterocyclic ring is a monocyclic ring;
- n 0 or 1
- R 4 is independently C 1-6 alkyl, or C 1-6 alkyl substituted with one or more R 4-1;
- R 4e and R 4f are independently hydrogen or a C 1-6 alkyl group; for example, hydrogen.
- n 0 or 1
- R 4 is independently C 1-6 alkyl substituted with one or more R 4-1;
- R 4e and R 4f are independently hydrogen or C 1-6 alkyl; for example, hydrogen.
- n 0 or 1
- R 4 is independently C 1-6 alkyl, or C 1-6 alkyl substituted with one or more R 4-1;
- R 4-1 is independently a hydroxyl group or a cyano group.
- n 0 or 1
- R 4 is independently C 1-6 alkyl, or C 1-6 alkyl substituted with one or more R 4-1;
- R 4-1 is independently a hydroxyl group.
- n 0 or 1
- R 4 is independently C 1-6 alkyl, or C 1-6 alkyl substituted with one or more R 4-1;
- R 4-1 is independently cyano.
- R a is independently hydrogen or halogen
- R b-1 is independently -NR 10j R 10k ;
- R 10j and R 10k are independently hydrogen or C 1-6 alkyl, or, R 10j , R 10k and the N connected to them together form "containing 1-3 heteroatoms, and the heteroatoms are one of O and N One or more 4-6 membered heterocycloalkyl".
- R a is independently hydrogen
- R a is independently hydrogen or halogen
- R b and R f are independently hydrogen, C 1-6 alkyl, or C 1-6 alkyl substituted with one or more R b-1;
- R b-1 is independently halogen, hydroxyl, C 1-6 alkoxy, or -NR 10j R 10k ;
- R 10j and R 10k are independently hydrogen or C 1-6 alkyl, or, R 10j , R 10k and the N connected to them together form "containing 1-3 heteroatoms, and the heteroatoms are one of O and N One or more 4-6 membered heterocycloalkyl".
- R a is independently hydrogen or halogen
- R b and R f are independently hydrogen, C 1-6 alkyl, or C 1-6 alkyl substituted with one or more R b-1;
- R b-1 is independently -NR 10j R 10k ;
- R 10j and R 10k are independently hydrogen or C 1-6 alkyl, or, R 10j , R 10k and the N connected to them together form "containing 1-3 heteroatoms, and the heteroatoms are one of O and N One or more 4-6 membered heterocycloalkyl".
- R 1 is a C 6-20 aryl group, a "5-12 membered heteroaryl group containing 1-4 heteroatoms, and one or more of O, S and N", and one or more R 1-6 substituted C 6-20 aryl, or, substituted by one or more R 1-7 "containing 1-4 heteroatoms, heteroatoms are one or more of O, S and N 5-12 membered heteroaryl";
- R 1-6 and R 1-7 independently halo, C 1-6 alkyl, substituted with one or more R 1-6-1 C 1-6 alkyl group; R 1-6-1 is independently halogen;
- n 0;
- R 3 is -OR 31 , -SR 32 or -NR 33 R 34 ;
- R 31 , R 32 and R 34 are independently C 1-6 alkyl substituted by one or more R 31-1 ;
- R 33 is independently H, C 1-6 alkyl or by one or more R 31 -1 substituted C 1-6 alkyl; for example, H or C 1-6 alkyl;
- R 31-1 is independently a "5-7 membered heterocycloalkyl containing 1 to 3 heteroatoms and one or more of O and N" substituted by one or more R d15, or , -NR e1 R e2 ;
- R d15 is independently C 1-6 alkyl or halogen
- R e1 and R e2 are independently C 1-6 alkyl
- Ring Y is a 4-12 membered heterocyclic ring containing 1-4 N atoms; the heterocyclic ring is a saturated heterocyclic ring or a partially saturated heterocyclic ring; the heterocyclic ring is a monocyclic ring or a spiro ring;
- G is N, C or CH
- n 0 or 1
- R 4 is independently C 1-6 alkyl, or C 1-6 alkyl substituted with one or more R 4-1;
- R 4e and R 4f are independently hydrogen or C 1-6 alkyl;
- R a is independently hydrogen or halogen
- R b-1 is independently halogen, hydroxyl, C 1-6 alkoxy, or -NR 10j R 10k ;
- R 10j and R 10k are independently hydrogen or C 1-6 alkyl, or, R 10j , R 10k and the N connected to them together form "containing 1-3 heteroatoms, and the heteroatoms are one of O and N One or more 4-6 membered heterocycloalkyl".
- R 1 is a C 6-20 aryl group, a "5-12 membered heteroaryl group containing 1-4 heteroatoms, and one or more of O, S and N", and one or more R 1-6 substituted C 6-20 aryl, or, substituted by one or more R 1-7 "containing 1-4 heteroatoms, heteroatoms are one or more of O, S and N 5-12 membered heteroaryl";
- R 1-6 and R 1-7 are independently halogen, hydroxy, C 1-6 alkyl, C 1-6 alkoxy, C 3-10 cycloalkyl, substituted by one or more R 1-6-1 Substituted C 1-6 alkyl, or C 1-6 alkoxy substituted with one or more R 1-6-2 ; R 1-6-1 and R 1-6-2 are independently halogen;
- n 0;
- R 3 is -OR 31 or -NR 33 R 34 ;
- R 31 , R 33 and R 34 are independently C 1-6 alkyl substituted with one or more R 31-1;
- R 31-1 is independently a "5-7 membered heterocycloalkyl group containing 1-3 heteroatoms and one or more of O and N" substituted by one or more R d15, or , -NR e1 R e2 ;
- R 1-8-1 is independently halogen;
- R e5 , R e6 , R e7 and R e8 are independently hydrogen or C 1-6 alkyl;
- R e1 and R e2 are independently C 1-6 alkyl
- Ring Y is a 4-12 membered heterocyclic ring containing 1-4 N atoms; the heterocyclic ring is a saturated heterocyclic ring or a partially saturated heterocyclic ring; the heterocyclic ring is a monocyclic ring or a spiro ring;
- G is N, C or CH
- n 0 or 1
- R 4 is independently C 1-6 alkyl, or C 1-6 alkyl substituted with one or more R 4-1;
- R 4-1 is independently a cyano group or a hydroxyl group
- R a is independently hydrogen or halogen
- R b and R f are independently hydrogen, C 1-6 alkyl, or C 1-6 alkyl substituted with one or more R b-1;
- R b-1 is independently halogen, hydroxyl, C 1-6 alkoxy, or -NR 10j R 10k ;
- R 10j and R 10k are independently hydrogen or C 1-6 alkyl, or, R 10j , R 10k and the N connected to them together form "containing 1-3 heteroatoms, and the heteroatoms are one of O and N One or more 4-6 membered heterocycloalkyl".
- R 1 is a C 6-20 aryl group, "a 5-12 membered heteroaryl group containing 1-4 heteroatoms, and one or more of O, S, and N", and one or more R 1-6 substituted C 6-20 aryl, or, substituted by one or more R 1-7 "containing 1-4 heteroatoms, heteroatoms are one or more of O, S and N 5-12 membered heteroaryl";
- R 1-6 and R 1-7 are independently halogen, hydroxy, C 1-6 alkyl, C 1-6 alkoxy, C 3-10 cycloalkyl, substituted by one or more R 1-6-1 Substituted C 1-6 alkyl, or C 1-6 alkoxy substituted with one or more R 1-6-2 ; R 1-6-1 and R 1-6-2 are independently halogen;
- n 0;
- R 3 is -OR 31 or -NR 33 R 34 ;
- R 31 , R 33 and R 34 are independently C 1-6 alkyl substituted with one or more R 31-1;
- R 31-1 is independently a "5-7 membered heterocycloalkyl group containing 1-3 heteroatoms and one or more of O and N" substituted by one or more R d15, or , -NR e1 R e2 ;
- R 1-8-1 is independently halogen;
- R e5 , R e6 , R e7 and R e8 are independently hydrogen or C 1-6 alkyl;
- R e1 and R e2 are independently C 1-6 alkyl
- Ring Y is a 4-12 membered heterocyclic ring containing 1-4 N atoms; the heterocyclic ring is a saturated heterocyclic ring or a partially saturated heterocyclic ring; the heterocyclic ring is a monocyclic ring or a spiro ring;
- G is N, C or CH
- n 0 or 1
- R 4 is independently C 1-6 alkyl, or C 1-6 alkyl substituted with one or more R 4-1;
- R 4-1 is independently cyano
- R a is independently hydrogen or halogen
- R b and R f are independently hydrogen, C 1-6 alkyl, or C 1-6 alkyl substituted with one or more R b-1;
- R b-1 is independently halogen, hydroxyl, C 1-6 alkoxy, or -NR 10j R 10k ;
- R 10j and R 10k are independently hydrogen or C 1-6 alkyl, or, R 10j , R 10k and the N connected to them together form "containing 1-3 heteroatoms, and the heteroatoms are one of O and N One or more 4-6 membered heterocycloalkyl".
- R 1 is a C 6-20 aryl group, a "5-12 membered heteroaryl group containing 1-4 heteroatoms, and one or more of O, S and N", and one or more R 1-6 substituted C 6-20 aryl, or, substituted by one or more R 1-7 "containing 1-4 heteroatoms, heteroatoms are one or more of O, S and N 5-12 membered heteroaryl group"; for example, C 6-20 aryl group, "5-12 membered heteroaryl group containing 1-4 heteroatoms, and heteroatoms are one or more of O, S and N" , Or, C 6-20 aryl substituted with one or more R 1-6;
- R 1-6 is independently halogen, C 1-6 alkyl, or C 1-6 alkyl substituted with one or more R 1-6-1;
- R 1-6-1 is independently halogen
- n 0;
- R 3 is -OR 31 , -SR 32 or -NR 33 R 34 ;
- R 31 , R 32 and R 34 are independently C 1-6 alkyl substituted by one or more R 31-1 ;
- R 33 is independently H, C 1-6 alkyl or by one or more R 31 -1 substituted C 1-6 alkyl; for example, H or C 1-6 alkyl;
- R 31-1 is independently a "5-7 membered heterocycloalkyl group containing 1-3 heteroatoms and one or more of O and N" substituted by one or more R d15, or , -NR e1 R e2 ;
- R d15 is independently C 1-6 alkyl or halogen
- R e1 and R e2 are independently C 1-6 alkyl
- Ring Y is a 4-12 membered heterocyclic ring containing 1-4 N atoms; the heterocyclic ring is a saturated heterocyclic ring or a partially saturated heterocyclic ring; the heterocyclic ring is a monocyclic ring;
- G is N
- n 0 or 1
- R 4 is independently C 1-6 alkyl substituted with one or more R 4-1;
- R 4e and R 4f are independently hydrogen or C 1-6 alkyl;
- R a is independently hydrogen or halogen
- R 1 is a C 6-20 aryl group, or a C 6-20 aryl group substituted by one or more R 1-6;
- R 1-6 is independently halogen, C 1-6 alkyl, or C 1-6 alkyl substituted with one or more R 1-6-1;
- R 1-6-1 is independently halogen
- n 0;
- R 3 is -OR 31 or -NR 33 R 34 ;
- R 31 , R 33 and R 34 are independently C 1-6 alkyl substituted with one or more R 31-1;
- R 31-1 is independently a "5-7 membered heterocycloalkyl group containing 1-3 heteroatoms and one or more of O and N" substituted by one or more R d15, or , -NR e1 R e2 ;
- R d15 is independently C 1-6 alkyl or halogen
- R e1 and R e2 are independently C 1-6 alkyl
- Ring Y is a 4-12 membered heterocyclic ring containing 1-4 N atoms; the heterocyclic ring is a saturated heterocyclic ring or a partially saturated heterocyclic ring; the heterocyclic ring is a monocyclic ring;
- G is N
- n 0 or 1
- R 4 is independently C 1-6 alkyl, or C 1-6 alkyl substituted with one or more R 4-1;
- R 4-1 is independently cyano
- R a is independently hydrogen or halogen
- R b and R f are independently hydrogen or C 1-6 alkyl, or C 1-6 alkyl substituted with one or more R b-1;
- R b-1 is independently -NR 10j R 10k ;
- R 10j and R 10k are independently hydrogen or C 1-6 alkyl, or, R 10j , R 10k and the N connected to them together form "containing 1-3 heteroatoms, and the heteroatoms are one of O and N One or more 4-10 membered heterocycloalkyl".
- R 1 is a C 6-20 aryl group, or a C 6-20 aryl group substituted by one or more R 1-6;
- R 1-6 is independently halogen, C 1-6 alkyl, or C 1-6 alkyl substituted with one or more R 1-6-1;
- R 1-6-1 is independently halogen
- n 0;
- R 3 is -OR 31 or -NR 33 R 34 ;
- R 31 , R 33 and R 34 are independently C 1-6 alkyl substituted with one or more R 31-1;
- R 31-1 is independently a "5-7 membered heterocycloalkyl group containing 1-3 heteroatoms and one or more of O and N" substituted by one or more R d15, or , -NR e1 R e2 ;
- R e1 , R e2 and R d15 are independently C 1-6 alkyl
- Ring Y is a 4-12 membered heterocyclic ring containing 1-4 N atoms; the heterocyclic ring is a saturated heterocyclic ring or a partially saturated heterocyclic ring; the heterocyclic ring is a monocyclic ring;
- G is N
- n 0 or 1
- R 4 is independently C 1-6 alkyl, or C 1-6 alkyl substituted with one or more R 4-1;
- R 4-1 is independently cyano
- R a is independently hydrogen or halogen
- R b and R f are independently hydrogen or C 1-6 alkyl.
- the structure of the oxygen-containing heterocyclic compound shown in formula I is as follows: For example, their molar ratio is 1:1".
- the C 6-20 aryl group may be a phenyl group or a naphthyl group, or a phenyl group or a 1-naphthyl group.
- the said R 1 is "a 5-12 membered heteroaryl containing 1-4 heteroatoms, and the heteroatom is one or more of O, S and N"
- the said "containing 1-4 A 5-12 membered heteroaryl group containing one heteroatom, one or more of O, S, and N” may be “containing 1-4 heteroatoms, and the heteroatom is one of O, S, and N
- One or more kinds of 9-10 membered heteroaryl groups” can also be “a 9-10 membered heteroaryl group containing one heteroatom, and the heteroatom is one of O, S, and N", and can also be different Quinolinyl can also be
- the C 6-20 aryl group may be a phenyl group or a naphthyl group, or a phenyl group or a -Naphthyl.
- the plurality may be 2 or 3.
- said halogen may be fluorine, chlorine, bromine or iodine, and may also be fluorine or chlorine.
- the C 1-6 alkyl group may be a C 1-4 alkyl group, or may be methyl, ethyl, n-propyl, Isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl may also be methyl.
- the C 1-6 alkyl group may be a C 1-4 alkyl group, It can also be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl, and can also be methyl.
- the plurality of R 1-6 may be two or three.
- the halogen may be fluorine, chlorine, bromine or iodine, or may be fluorine.
- R 1-6 is independently C 1-6 alkyl substituted by one or more R 1-6-1
- said C 1 substituted by one or more R 1-6-1 may be trifluoromethyl.
- the C 1-6 alkyl group may be a C 1-4 alkyl group, or may be methyl, ethyl, n-propyl, isopropyl Group, n-butyl, isobutyl, sec-butyl or tert-butyl, and may also be methyl, ethyl, n-propyl or isopropyl.
- the C 1-6 alkyl may be C 1-4 alkane Group, which can be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl, and can also be methyl, ethyl, n-propyl or isopropyl base.
- R 31 , R 33 and R 34 are independently C 1-6 alkyl substituted with one or more R 31-1 , the plurality of R 31, R 33 and R 34 may be two or three.
- R 31-1 is independently substituted by one or more R d15 , "a 4-10 membered heterocycloalkane containing 1-3 heteroatoms and one or more of O and N heteroatoms
- the “4-10 membered heterocycloalkyl group containing 1-3 heteroatoms and one or more of O and N” may be “containing 1-3 heteroatoms, Heteroatom is one or more of O and N 5-7 membered heterocycloalkyl", it can also be "a 5-7 membered heteroatom containing one heteroatom, heteroatom is one of O and N 5-7
- Cycloalkyl may also be tetrahydropyrrolyl or tetrahydropyrrol-2-yl.
- R 31-1 is independently substituted by one or more R d15 , "a 4-10 membered heterocycloalkane containing 1-3 heteroatoms and one or more of O and N heteroatoms
- the number of said multiple may be 2 or 3.
- the C 1-6 alkyl group may be a C 1-4 alkyl group, or may be methyl, ethyl, n-propyl, isopropyl Group, n-butyl, isobutyl, sec-butyl or tert-butyl, and may also be methyl.
- the halogen may be fluorine, chlorine, bromine or iodine, or may be fluorine.
- the C 1-6 alkyl may be C 1-4 alkyl, or may be methyl, ethyl, or n-propyl. , Isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl, and can also be methyl or ethyl.
- R 31 , R 33 and R 34 are independently C 1-6 alkyl substituted by one or more R 31-1 , said C 1 substituted by one or more R 31-1
- the -6 alkyl group can be
- the 4-12 membered heterocyclic ring containing 1-4 N atoms may be one containing 1-2 N atoms 6-9 membered heterocyclic ring, which can also be Its upper end is connected to R 2 .
- the C 1-6 alkyl group may be a C 1-4 alkyl group, or may be methyl, ethyl, n-propyl, isopropyl Group, n-butyl, isobutyl, sec-butyl or tert-butyl, and may also be methyl.
- the C 1-6 alkyl group may be a C 1-4 alkyl group or a methyl group.
- the plurality of R 4 may be 2 or 3.
- R 4 is 4-1 independently substituted with one or more R C 1-6 alkyl group
- said one or more R & lt 4-1 alkyl substituted with C 1- 6 can be Hydroxymethyl, cyanomethyl or Such as cyanomethyl or
- R 4 is 4-1 independently substituted with one or more R C 1-6 alkyl group
- said one or more R & lt 4-1 alkyl substituted with C 1- 6 can be
- R 4 is 4-1 independently substituted with one or more R C 1-6 alkyl group
- said one or more R & lt 4-1 alkyl substituted with C 1- 6 can be Hydroxymethyl or cyanomethyl.
- R 4 is 4-1 independently substituted with one or more R C 1-6 alkyl group
- said one or more R & lt 4-1 alkyl substituted with C 1- 6 can be Hydroxymethyl.
- R 4 is 4-1 independently substituted with one or more R C 1-6 alkyl group
- said one or more R & lt 4-1 alkyl substituted with C 1- 6 can be Cyanomethyl.
- said halogen may be fluorine, chlorine, bromine or iodine, or may be fluorine.
- the C 1-6 alkyl may be C 1-4 alkyl, or may be methyl, ethyl, or n-propyl , Isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl, and may also be methyl.
- said C 1-6 alkyl -C ( O) - in a C 1-6 alkoxy
- the group may be a C 1-4 alkyl group, or may be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl, and may also be methyl.
- said C 1-6 alkyl may be C 1-4 alkyl, and It can be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl, and it can also be methyl.
- the plurality may be two or three.
- the C 1-6 alkyl may be C 1-4 alkyl, or may be methyl, ethyl, or n-propyl , Isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl, and may also be methyl.
- R 10j and R 10k and the N connected to them together form a "4-10 membered heterocycloalkyl group containing 1-3 heteroatoms, and the heteroatoms are one or more of O and N"
- the “4-10 membered heterocycloalkyl group containing 1-3 heteroatoms, one or more of O and N” may be “containing 2 heteroatoms, heteroatoms are O and N’s 5-6 membered heterocycloalkyl", which can also be
- the R 2 can be CN, In a scheme:
- the R 2 can be CN
- the R 2 can be any suitable R 2
- the R 2 can be any suitable R 2
- the oxygen-containing heterocyclic compound represented by formula I has any of the following structures:
- oxygen-containing heterocyclic compound represented by formula I is any of the following compounds:
- oxygen-containing heterocyclic compound represented by formula I is any of the following compounds:
- the present invention also provides a method for preparing the above-mentioned oxygen-containing heterocyclic compound represented by formula I, which is route one or route two:
- R 1 , R 2 , R 3 , R 4 , G, n, and Y have the same definitions as described above,
- X 1 is a leaving group (for example, OTf, Cl)
- Alk is an alkyl group (for example, C 1- 6 alkyl)
- PG is an amino protecting group (e.g. Boc, Cbz);
- R 1 , R 2 , R 3 , R 4 , G, n, and Y have the same definitions as described above, X 3 is a leaving group (for example, OTf, Cl), and PG is an amino protecting group (for example, Boc, Cbz).
- X 3 is a leaving group (for example, OTf, Cl)
- PG is an amino protecting group (for example, Boc, Cbz).
- aldehyde compound A1 is condensed with acetoacetate to obtain compound A2
- A2 is condensed with DMF-DMA to obtain compound A3
- A3 is reduced to A4
- A4 forms a ring after forming A5, A5
- the hydroxyl group is converted into a leaving group to obtain A6,
- A6 is converted to A7 by nucleophilic substitution or coupling,
- A7 is oxidized to obtain A8,
- A8 is further converted to A9, and A9 is deprotected, and further converted to A11.
- the detailed description of the second route can be as follows: Compound A5 is protected with Bn, C1 is oxidized to obtain C2, C2 is converted to C3 by nucleophilic substitution, C3 is converted to C4 by removing Bn protection, and the hydroxyl group in C4 is converted to a leaving group. The group gets C5, C5 is converted into A9 by nucleophilic substitution or coupling, and A9 is deprotected, and further converted into A11.
- the present invention also provides a compound represented by formula A5, A6, A7, A8, A9, A10, C1, C2, C3, C4 or C5;
- R 1 , R 3 , R 4 , G, Y and n are as defined above;
- X 1 and X 3 are independently leaving groups (for example, OTf, Cl), and PG is an amino protecting group (for example, Boc, Cbz).
- the compound represented by formula A5, A6, A7, A8, A9, A10, C1, C2, C3, C4 or C5 can be any of the following compounds:
- the present invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising substance A and pharmaceutical excipients; said substance A is the above-mentioned oxygen-containing heterocyclic compound represented by formula I, its pharmaceutically acceptable salt, and its stereo Isomers, tautomers or isotopic compounds thereof.
- the present invention also provides an application of substance A in the preparation of RAS inhibitors.
- Said substance A is the above-mentioned oxygen-containing heterocyclic compound represented by formula I, its pharmaceutically acceptable salts, and its stereoisomers. Body, its tautomer or its isotope compound.
- the RAS is, for example, KRAS G12C, HRAS G12C, or NRAS G12C mutation; for example, KRAS G12C.
- the present invention also provides the application of substance A in the preparation of medicines, which are used to treat or prevent RAS-mediated diseases;
- the substance A is the above-mentioned oxygen-containing heterocyclic compound represented by formula I, its pharmaceutically acceptable salt, its stereoisomer, its tautomer or its isotopic compound.
- the RAS is, for example, KRAS G12C, HRAS G12C, or NRAS G12C mutation; for example, KRAS G12C.
- the RAS-mediated diseases are cancers.
- the cancer for example, colon cancer, pancreatic cancer, breast cancer, prostate cancer, lung cancer, brain cancer, ovarian cancer, cervical cancer, testicular cancer, kidney cancer, head or neck cancer, bone cancer, skin cancer, rectal cancer, liver cancer , Colon cancer, esophageal cancer, stomach cancer, pancreatic cancer, thyroid cancer, bladder cancer, lymphoma, leukemia, and melanoma.
- the present invention also provides an application of substance A in the preparation of medicines, which are used to treat or prevent cancer;
- the substance A is the above-mentioned oxygen-containing heterocyclic compound represented by formula I, its pharmaceutically acceptable salt, its stereoisomer, its tautomer or its isotopic compound.
- the cancer for example, colon cancer, pancreatic cancer, breast cancer, prostate cancer, lung cancer, brain cancer, ovarian cancer, cervical cancer, testicular cancer, kidney cancer, head or neck cancer, bone cancer, skin cancer, rectal cancer, liver cancer , Colon cancer, esophageal cancer, stomach cancer, pancreatic cancer, thyroid cancer, bladder cancer, lymphoma, leukemia, and melanoma.
- the present invention also provides an oxygen-containing heterocyclic compound represented by formula I, its pharmaceutically acceptable salt, its solvate, its pharmaceutically acceptable salt solvate, its crystal form, its stereo Isomers, tautomers or isotopic compounds:
- R 1 is a C 6-20 aryl group, "a 5-12 membered heteroaryl group containing 1-4 heteroatoms, and one or more of O, S and N", and one or more A C 6-20 aryl group substituted by R 1-6 , or a C 6-20 aryl group substituted by one or more R 1-7 "containing 1-4 heteroatoms, the heteroatoms are one or more of O, S and N Species of 5-12 membered heteroaryl";
- R 65 , R 65-2 , R 63 , R 63-2 , R 64 , R 64-2 , R 66 , R 66-2 , R 69 , R 69-2 , R 610 and R 610-2 are independently Hydrogen or C 1-6 alkyl;
- n 0, 1 or 2;
- R 5 is independently C 1-6 alkyl
- R 3 is -OR 31 , -SR 32 or -NR 33 R 34 ;
- R 31 , R 32 and R 34 are independently C 1-6 alkyl substituted by one or more R 31-1 ;
- R 33 is independently H, C 1-6 alkyl, or by one or more R 31-1 substituted C 1-6 alkyl;
- R d , R d1 , Re1 , Re2 , Re3 and Re4 are independently hydrogen, C 1-6 alkyl, C 3-10 cycloalkyl, "containing 1-3 heteroatoms, and the heteroatom is O And one or more 4-10 membered heterocycloalkyl groups in N", or C 1-6 alkyl substituted by one or more R 1-8-2;
- R e5 , R e6 , R e7 , R e8 , R e9 , R e10 , R e11 , R e12 , R e13 and R e14 are independently hydrogen or C 1-6 alkyl;
- Ring Y is a 4-12 membered heterocyclic ring containing 1-4 N atoms; the heterocyclic ring is a saturated heterocyclic ring or a partially saturated heterocyclic ring; the heterocyclic ring is a monocyclic ring, a bridged ring or a spiro ring;
- G is N, C or CH
- n 0, 1, 2 or 3;
- R 4d , R 4e , R 4f , R 4i and R 4j are independently hydrogen or C 1-6 alkyl;
- R 4a , R 4b and R 4c are independently hydrogen or C 1-6 alkyl
- R a is independently hydrogen, deuterium, halogen or C 1-6 alkyl
- R b-1 is independently halogen, hydroxyl, C 1-6 alkoxy, or -NR 10j R 10k ;
- R 10j and R 10k are independently hydrogen or C 1-6 alkyl, or, R 10j , R 10k and the N connected to them together form "containing 1-3 heteroatoms, and the heteroatoms are one of O and N One or more 4-10 membered heterocycloalkyl".
- the oxygen-containing heterocyclic compound represented by formula I its pharmaceutically acceptable salt, its solvate, its pharmaceutically acceptable salt solvate, its crystal form, its stereo
- certain groups have the following definitions, and the definitions of unmentioned groups are as described in any of the schemes of the present invention (the content of this paragraph is hereinafter referred to as "in a certain In one scheme"), the oxygen-containing heterocyclic compound shown in formula I,
- R 1 is a C 6-20 aryl group, "a 5-12 membered heteroaryl group containing 1-4 heteroatoms, and one or more of O, S and N", and one or more A C 6-20 aryl group substituted by R 1-6 , or a C 6-20 aryl group substituted by one or more R 1-7 "containing 1-4 heteroatoms, the heteroatoms are one or more of O, S and N Species of 5-12 membered heteroaryl";
- R 65 , R 65-2 , R 63 , R 63-2 , R 64 , R 64-2 , R 66 , R 66-2 , R 69 , R 69-2 , R 610 and R 610-2 are independently Hydrogen or C 1-6 alkyl;
- n 0, 1 or 2;
- R 5 is independently C 1-6 alkyl
- R 3 is -OR 31 , -SR 32 or -NR 33 R 34 ;
- R 31 , R 32 , R 33 and R 34 are independently C 1-6 alkyl substituted with one or more R 31-1;
- R d , R d1 , Re1 , Re2 , Re3 and Re4 are independently hydrogen, C 1-6 alkyl, C 3-10 cycloalkyl, "containing 1-3 heteroatoms, and the heteroatom is O And one or more 4-10 membered heterocycloalkyl groups in N", or C 1-6 alkyl substituted by one or more R 1-8-2;
- R e5 , R e6 , R e7 , R e8 , R e9 , R e10 , R e11 , R e12 , R e13 and R e14 are independently hydrogen or C 1-6 alkyl;
- Ring Y is a 4-12 membered heterocyclic ring containing 1-4 N atoms; the heterocyclic ring is a saturated heterocyclic ring or a partially saturated heterocyclic ring; the heterocyclic ring is a monocyclic ring, a bridged ring or a spiro ring;
- G is N, C or CH
- n 0, 1, 2 or 3;
- R 4d , R 4e , R 4f , R 4i and R 4j are independently hydrogen or C 1-6 alkyl;
- R 4a , R 4b and R 4c are independently hydrogen or C 1-6 alkyl
- R a is independently hydrogen, deuterium, halogen or C 1-6 alkyl
- R b and R f are independently hydrogen, deuterium, C 1-6 alkyl, or C 1-6 alkyl substituted with one or more R b-1;
- R b-1 is independently halogen, hydroxyl, C 1-6 alkoxy, or -NR 10j R 10k ;
- R 10j and R 10k are independently hydrogen or C 1-6 alkyl, or, R 10j , R 10k and the N connected to them together form "containing 1-3 heteroatoms, and the heteroatoms are one of O and N One or more 4-10 membered heterocycloalkyl".
- R 1 is a C 6-20 aryl group, "a 5-12 membered heteroaryl group containing 1-4 heteroatoms, and one or more of O, S, and N", and one or more R 1-6 substituted C 6-20 aryl, or, substituted by one or more R 1-7 "containing 1-4 heteroatoms, heteroatoms are one or more of O, S and N 5-12 membered heteroaryl";
- R 1-6 and R 1-7 are independently halogen, hydroxy, C 1-6 alkyl, C 1-6 alkoxy, C 3-10 cycloalkyl, substituted by one or more R 1-6-1 A substituted C 1-6 alkyl group or a C 1-6 alkoxy group substituted with one or more R 1-6-2 ; R 1-6-1 and R 1-6-2 are independently halogen.
- R 1 is a C 6-20 aryl group, a "5-12 membered heteroaryl group containing 1-4 heteroatoms, and one or more of O, S and N", and one or more R 1-6 substituted C 6-20 aryl, or, substituted by one or more R 1-7 "containing 1-4 heteroatoms, heteroatoms are one or more of O, S and N 5-12 membered heteroaryl group"; for example, C 6-20 aryl group, "5-12 membered heteroaryl group containing 1-4 heteroatoms, and heteroatoms are one or more of O, S and N" , Or, C 6-20 aryl substituted with one or more R 1-6;
- R 1-6 and R 1-7 are independently halogen, C 1-6 alkyl, or C 1-6 alkyl substituted with one or more R 1-6-1;
- R 1-6-1 is independently halogen.
- R 1 is a C 6-20 aryl group, or a C 6-20 aryl group substituted by one or more R 1-6;
- R 1-6 is independently halogen, C 1-6 alkyl, or C 1-6 alkyl substituted with one or more R 1-6-1;
- R 1-6-1 is independently halogen.
- R 3 is -OR 31 , -SR 32 or -NR 33 R 34 ;
- R 31 , R 32 and R 34 are independently C 1-6 alkyl substituted by one or more R 31-1 ;
- R 33 is independently H, C 1-6 alkyl, or by one or more R 31-1 substituted C 1-6 alkyl;
- R 31-1 is independently a "5-7 membered heterocycloalkyl group containing 1-3 heteroatoms and one or more of O and N" substituted by one or more R d15, or , -NR e1 R e2 ;
- R 1-8-1 is independently halogen;
- R e5 , R e6 , R e7 and R e8 are independently hydrogen or C 1-6 alkyl;
- R e1 and R e2 are independently C 1-6 alkyl.
- R 3 is -SR 32 ;
- R 32 is C 1-6 alkyl substituted by one or more R 31-1;
- R 31-1 is independently -NR e1 R e2 ;
- R e1 and R e2 are independently C 1-6 alkyl.
- R 3 is -OR 31 or -NR 33 R 34 ;
- R 31 , R 33 and R 34 are independently C 1-6 alkyl substituted with one or more R 31-1;
- R 31-1 is independently a "5-7 membered heterocycloalkyl group containing 1-3 heteroatoms and one or more of O and N" substituted by one or more R d15, or , -NR e1 R e2 ;
- R 1-8-1 is independently halogen;
- R e5 , R e6 , R e7 and R e8 are independently hydrogen or C 1-6 alkyl;
- R e1 and R e2 are independently C 1-6 alkyl.
- R 3 is -NR 33 R 34 ;
- R 34 is independently substituted with one or more R 31-1 substituted with C 1-6 alkyl;
- R 33 is independently H, C 1-6 alkyl or with one or more R 31- 1-substituted C 1 -6 alkyl; such as H or C 1-6 alkyl;
- R 31-1 is independently a "5-7 membered heterocycloalkyl group containing 1-3 heteroatoms and one or more of O and N" substituted by one or more R d15, or , -NR e1 R e2 ;
- R d15 is independently C 1-6 alkyl
- R e1 and R e2 are independently C 1-6 alkyl.
- R 3 is -OR 31 or -NR 33 R 34 ;
- R 31 and R 34 are independently C 1-6 alkyl substituted by one or more R 31-1 ;
- R 33 are independently H, C 1-6 alkyl or substituted by one or more R 31-1 ⁇ C 1-6 alkyl; for example, H or C 1-6 alkyl;
- R 31-1 is independently a "5-7 membered heterocycloalkyl group containing 1-3 heteroatoms and one or more of O and N" substituted by one or more R d15, or , -NR e1 R e2 ;
- R d15 is independently C 1-6 alkyl or halogen
- R e1 and R e2 are independently C 1-6 alkyl.
- R 3 is -OR 31 or -NR 33 R 34 ;
- R 31 , R 33 and R 34 are independently C 1-6 alkyl substituted with one or more R 31-1;
- R 31-1 is independently a "5-7 membered heterocycloalkyl group containing 1-3 heteroatoms and one or more of O and N" substituted by one or more R d15, or , -NR e1 R e2 ;
- R d15 is independently C 1-6 alkyl or halogen
- R e1 and R e2 are independently C 1-6 alkyl.
- R 3 is -NR 33 R 34 ;
- R 33 and R 34 are independently C 1-6 alkyl substituted with one or more R 31-1;
- R 31-1 is independently a "5-7 membered heterocycloalkyl containing 1 to 3 heteroatoms and one or more of O and N" substituted by one or more R d15;
- R d15 is independently C 1-6 alkyl.
- R 3 is -OR 31 or -NR 33 R 34 ;
- R 31 , R 33 and R 34 are independently C 1-6 alkyl substituted with one or more R 31-1;
- R 31-1 is independently a "5-7 membered heterocycloalkyl group containing 1-3 heteroatoms and one or more of O and N" substituted by one or more R d15, or , -NR e1 R e2 ;
- R e1 , R e2 and R d15 are independently C 1-6 alkyl.
- Ring Y is a 4-12 membered heterocyclic ring containing 1-4 N atoms; the heterocyclic ring is a saturated heterocyclic ring or a partially saturated heterocyclic ring; the heterocyclic ring is a monocyclic or spiro ring; for example, a monocyclic ring;
- G is N, C or CH.
- Ring Y is a 4-12 membered heterocyclic ring containing 1-4 N atoms; the heterocyclic ring is a saturated heterocyclic ring or a partially saturated heterocyclic ring; the heterocyclic ring is a monocyclic ring;
- n 0 or 1
- R 4 is independently C 1-6 alkyl, or C 1-6 alkyl substituted with one or more R 4-1;
- R 4e and R 4f are independently hydrogen or a C 1-6 alkyl group; for example, hydrogen.
- n 0 or 1
- R 4 is independently C 1-6 alkyl substituted with one or more R 4-1;
- R 4e and R 4f are independently hydrogen or C 1-6 alkyl; for example, hydrogen.
- n 0 or 1
- R 4 is independently C 1-6 alkyl, or C 1-6 alkyl substituted with one or more R 4-1;
- R 4-1 is independently a hydroxyl group or a cyano group.
- n 0 or 1
- R 4 is independently C 1-6 alkyl, or C 1-6 alkyl substituted with one or more R 4-1;
- R 4-1 is independently a hydroxyl group.
- n 0 or 1
- R 4 is independently C 1-6 alkyl, or C 1-6 alkyl substituted with one or more R 4-1;
- R 4-1 is independently cyano.
- R a is independently hydrogen or halogen
- R b-1 is independently -NR 10j R 10k ;
- R 10j and R 10k are independently hydrogen or C 1-6 alkyl, or, R 10j , R 10k and the N connected to them together form "containing 1-3 heteroatoms, and the heteroatoms are one of O and N One or more 4-6 membered heterocycloalkyl".
- R a is independently hydrogen
- R a is independently hydrogen or halogen
- R b and R f are independently hydrogen, C 1-6 alkyl, or C 1-6 alkyl substituted with one or more R b-1;
- R b-1 is independently halogen, hydroxyl, C 1-6 alkoxy, or -NR 10j R 10k ;
- R 10j and R 10k are independently hydrogen or C 1-6 alkyl, or, R 10j , R 10k and the N connected to them together form "containing 1-3 heteroatoms, and the heteroatoms are one of O and N One or more 4-6 membered heterocycloalkyl".
- R a is independently hydrogen or halogen
- R b and R f are independently hydrogen, C 1-6 alkyl, or C 1-6 alkyl substituted with one or more R b-1;
- R b-1 is independently -NR 10j R 10k ;
- R 10j and R 10k are independently hydrogen or C 1-6 alkyl, or, R 10j , R 10k and the N connected to them together form "containing 1-3 heteroatoms, and the heteroatoms are one of O and N One or more 4-6 membered heterocycloalkyl".
- R 1 is a C 6-20 aryl group, "a 5-12 membered heteroaryl group containing 1-4 heteroatoms, and one or more of O, S, and N", and one or more R 1-6 substituted C 6-20 aryl, or, substituted by one or more R 1-7 "containing 1-4 heteroatoms, heteroatoms are one or more of O, S and N 5-12 membered heteroaryl";
- R 1-6 and R 1-7 independently halo, C 1-6 alkyl, substituted with one or more R 1-6-1 C 1-6 alkyl group; R 1-6-1 is independently halogen;
- n 0;
- R 3 is -OR 31 , -SR 32 or -NR 33 R 34 ;
- R 31 , R 32 and R 34 are independently C 1-6 alkyl substituted by one or more R 31-1 ;
- R 33 is independently H, C 1-6 alkyl or by one or more R 31 -1 substituted C 1-6 alkyl; for example, H or C 1-6 alkyl;
- R 31-1 is independently a "5-7 membered heterocycloalkyl group containing 1-3 heteroatoms and one or more of O and N" substituted by one or more R d15, or , -NR e1 R e2 ;
- R d15 is independently C 1-6 alkyl or halogen
- R e1 and R e2 are independently C 1-6 alkyl
- Ring Y is a 4-12 membered heterocyclic ring containing 1-4 N atoms; the heterocyclic ring is a saturated heterocyclic ring or a partially saturated heterocyclic ring; the heterocyclic ring is a monocyclic ring or a spiro ring;
- G is N, C or CH
- n 0 or 1
- R 4 is independently C 1-6 alkyl, or C 1-6 alkyl substituted with one or more R 4-1;
- R 4e and R 4f are independently hydrogen or C 1-6 alkyl;
- R a is independently hydrogen or halogen
- R b-1 is independently halogen, hydroxyl, C 1-6 alkoxy, or -NR 10j R 10k ;
- R 10j and R 10k are independently hydrogen or C 1-6 alkyl, or, R 10j , R 10k and the N connected to them together form "containing 1-3 heteroatoms, and the heteroatoms are one of O and N One or more 4-6 membered heterocycloalkyl".
- R 1 is a C 6-20 aryl group, "a 5-12 membered heteroaryl group containing 1-4 heteroatoms, and one or more of O, S, and N", and one or more R 1-6 substituted C 6-20 aryl, or, substituted by one or more R 1-7 "containing 1-4 heteroatoms, heteroatoms are one or more of O, S and N 5-12 membered heteroaryl";
- R 1-6 and R 1-7 are independently halogen, hydroxy, C 1-6 alkyl, C 1-6 alkoxy, C 3-10 cycloalkyl, substituted by one or more R 1-6-1 Substituted C 1-6 alkyl, or C 1-6 alkoxy substituted with one or more R 1-6-2 ; R 1-6-1 and R 1-6-2 are independently halogen;
- n 0;
- R 3 is -OR 31 or -NR 33 R 34 ;
- R 31 , R 33 and R 34 are independently C 1-6 alkyl substituted with one or more R 31-1;
- R 31-1 is independently a "5-7 membered heterocycloalkyl group containing 1-3 heteroatoms and one or more of O and N" substituted by one or more R d15, or , -NR e1 R e2 ;
- R 1-8-1 is independently halogen;
- R e5 , R e6 , R e7 and R e8 are independently hydrogen or C 1-6 alkyl;
- R e1 and R e2 are independently C 1-6 alkyl
- Ring Y is a 4-12 membered heterocyclic ring containing 1-4 N atoms; the heterocyclic ring is a saturated heterocyclic ring or a partially saturated heterocyclic ring; the heterocyclic ring is a monocyclic ring or a spiro ring;
- G is N, C or CH
- n 0 or 1
- R 4 is independently C 1-6 alkyl, or C 1-6 alkyl substituted with one or more R 4-1;
- R 4-1 is independently a cyano group or a hydroxyl group
- R a is independently hydrogen or halogen
- R b and R f are independently hydrogen, C 1-6 alkyl, or C 1-6 alkyl substituted with one or more R b-1;
- R b-1 is independently halogen, hydroxyl, C 1-6 alkoxy, or -NR 10j R 10k ;
- R 10j and R 10k are independently hydrogen or C 1-6 alkyl, or, R 10j , R 10k and the N connected to them together form "containing 1-3 heteroatoms, and the heteroatoms are one of O and N One or more 4-6 membered heterocycloalkyl".
- R 1 is a C 6-20 aryl group, "a 5-12 membered heteroaryl group containing 1-4 heteroatoms, and one or more of O, S, and N", and one or more R 1-6 substituted C 6-20 aryl, or, substituted by one or more R 1-7 "containing 1-4 heteroatoms, heteroatoms are one or more of O, S and N 5-12 membered heteroaryl";
- R 1-6 and R 1-7 are independently halogen, hydroxy, C 1-6 alkyl, C 1-6 alkoxy, C 3-10 cycloalkyl, substituted by one or more R 1-6-1 Substituted C 1-6 alkyl, or C 1-6 alkoxy substituted with one or more R 1-6-2 ; R 1-6-1 and R 1-6-2 are independently halogen;
- n 0;
- R 3 is -OR 31 or -NR 33 R 34 ;
- R 31 , R 33 and R 34 are independently C 1-6 alkyl substituted with one or more R 31-1;
- R 31-1 is independently a "5-7 membered heterocycloalkyl group containing 1-3 heteroatoms and one or more of O and N" substituted by one or more R d15, or , -NR e1 R e2 ;
- R 1-8-1 is independently halogen;
- R e5 , R e6 , R e7 and R e8 are independently hydrogen or C 1-6 alkyl;
- R e1 and R e2 are independently C 1-6 alkyl
- Ring Y is a 4-12 membered heterocyclic ring containing 1-4 N atoms; the heterocyclic ring is a saturated heterocyclic ring or a partially saturated heterocyclic ring; the heterocyclic ring is a monocyclic ring or a spiro ring;
- G is N, C or CH
- n 0 or 1
- R 4 is independently C 1-6 alkyl, or C 1-6 alkyl substituted with one or more R 4-1;
- R 4-1 is independently cyano
- R a is independently hydrogen or halogen
- R b and R f are independently hydrogen, C 1-6 alkyl, or C 1-6 alkyl substituted with one or more R b-1;
- R b-1 is independently halogen, hydroxyl, C 1-6 alkoxy, or -NR 10j R 10k ;
- R 10j and R 10k are independently hydrogen or C 1-6 alkyl, or, R 10j , R 10k and the N connected to them together form "containing 1-3 heteroatoms, and the heteroatoms are one of O and N One or more 4-6 membered heterocycloalkyl".
- R 1 is a C 6-20 aryl group, a "5-12 membered heteroaryl group containing 1-4 heteroatoms, and one or more of O, S and N", and one or more R 1-6 substituted C 6-20 aryl, or, substituted by one or more R 1-7 "containing 1-4 heteroatoms, heteroatoms are one or more of O, S and N 5-12 membered heteroaryl group"; for example, C 6-20 aryl group, "5-12 membered heteroaryl group containing 1-4 heteroatoms, and heteroatoms are one or more of O, S and N" , Or, C 6-20 aryl substituted with one or more R 1-6;
- R 1-6 is independently halogen, C 1-6 alkyl, or C 1-6 alkyl substituted with one or more R 1-6-1;
- R 1-6-1 is independently halogen
- n 0;
- R 3 is -OR 31 , -SR 32 or -NR 33 R 34 ;
- R 31 , R 32 and R 34 are independently C 1-6 alkyl substituted by one or more R 31-1 ;
- R 33 is independently H, C 1-6 alkyl or by one or more R 31 -1 substituted C 1-6 alkyl; for example, H or C 1-6 alkyl;
- R 31-1 is independently a "5-7 membered heterocycloalkyl group containing 1-3 heteroatoms and one or more of O and N" substituted by one or more R d15, or , -NR e1 R e2 ;
- R d15 is independently C 1-6 alkyl or halogen
- R e1 and R e2 are independently C 1-6 alkyl
- Ring Y is a 4-12 membered heterocyclic ring containing 1-4 N atoms; the heterocyclic ring is a saturated heterocyclic ring or a partially saturated heterocyclic ring; the heterocyclic ring is a monocyclic ring;
- G is N
- n 0 or 1
- R 4 is independently C 1-6 alkyl substituted with one or more R 4-1;
- R 4e and R 4f are independently hydrogen or C 1-6 alkyl;
- R a is independently hydrogen or halogen
- R 1 is a C 6-20 aryl group, or a C 6-20 aryl group substituted by one or more R 1-6;
- R 1-6 is independently halogen, C 1-6 alkyl, or C 1-6 alkyl substituted with one or more R 1-6-1;
- R 1-6-1 is independently halogen
- n 0;
- R 3 is -OR 31 or -NR 33 R 34 ;
- R 31 , R 33 and R 34 are independently C 1-6 alkyl substituted with one or more R 31-1;
- R 31-1 is independently a "5-7 membered heterocycloalkyl group containing 1-3 heteroatoms and one or more of O and N" substituted by one or more R d15, or , -NR e1 R e2 ;
- R d15 is independently C 1-6 alkyl or halogen
- R e1 and R e2 are independently C 1-6 alkyl
- Ring Y is a 4-12 membered heterocyclic ring containing 1-4 N atoms; the heterocyclic ring is a saturated heterocyclic ring or a partially saturated heterocyclic ring; the heterocyclic ring is a monocyclic ring;
- G is N
- n 0 or 1
- R 4 is independently C 1-6 alkyl, or C 1-6 alkyl substituted with one or more R 4-1;
- R 4-1 is independently cyano
- R a is independently hydrogen or halogen
- R b and R f are independently hydrogen or C 1-6 alkyl, or C 1-6 alkyl substituted with one or more R b-1;
- R b-1 is independently -NR 10j R 10k ;
- R 10j and R 10k are independently hydrogen or C 1-6 alkyl, or, R 10j , R 10k and the N connected to them together form "containing 1-3 heteroatoms, and the heteroatoms are one of O and N One or more 4-10 membered heterocycloalkyl".
- R 1 is a C 6-20 aryl group, or a C 6-20 aryl group substituted by one or more R 1-6;
- R 1-6 is independently halogen, C 1-6 alkyl, or C 1-6 alkyl substituted with one or more R 1-6-1;
- R 1-6-1 is independently halogen
- n 0;
- R 3 is -OR 31 or -NR 33 R 34 ;
- R 31 , R 33 and R 34 are independently C 1-6 alkyl substituted with one or more R 31-1;
- R 31-1 is independently a "5-7 membered heterocycloalkyl group containing 1-3 heteroatoms and one or more of O and N" substituted by one or more R d15, or , -NR e1 R e2 ;
- R e1 , R e2 and R d15 are independently C 1-6 alkyl
- Ring Y is a 4-12 membered heterocyclic ring containing 1-4 N atoms; the heterocyclic ring is a saturated heterocyclic ring or a partially saturated heterocyclic ring; the heterocyclic ring is a monocyclic ring;
- G is N
- n 0 or 1
- R 4 is independently C 1-6 alkyl, or C 1-6 alkyl substituted with one or more R 4-1;
- R 4-1 is independently cyano
- R a is independently hydrogen or halogen
- R b and R f are independently hydrogen or C 1-6 alkyl.
- the structure of the oxygen-containing heterocyclic compound shown in formula I is as follows: For example, their molar ratio is 1:1".
- the C 6-20 aryl group may be a phenyl group or a naphthyl group, or a phenyl group or a 1-naphthyl group.
- the said R 1 is "a 5-12 membered heteroaryl containing 1-4 heteroatoms, and the heteroatom is one or more of O, S and N"
- the said "containing 1-4 A 5-12 membered heteroaryl group containing one heteroatom, one or more of O, S, and N” may be “containing 1-4 heteroatoms, and the heteroatom is one of O, S, and N
- One or more kinds of 9-10 membered heteroaryl groups” can also be “a 9-10 membered heteroaryl group containing one heteroatom, and the heteroatom is one of O, S, and N", and can also be different Quinolinyl can also be
- the C 6-20 aryl group may be a phenyl group or a naphthyl group, or a phenyl group or a -Naphthyl.
- the plurality may be 2 or 3.
- said halogen may be fluorine, chlorine, bromine or iodine, and may also be fluorine or chlorine.
- the C 1-6 alkyl group may be a C 1-4 alkyl group, or may be methyl, ethyl, n-propyl, Isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl may also be methyl.
- the C 1-6 alkyl group may be a C 1-4 alkyl group, It can also be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl, and can also be methyl.
- the plurality of R 1-6 may be two or three.
- the halogen may be fluorine, chlorine, bromine or iodine, or may be fluorine.
- R 1-6 is independently C 1-6 alkyl substituted by one or more R 1-6-1
- said C 1 substituted by one or more R 1-6-1 may be trifluoromethyl.
- the C 1-6 alkyl group may be a C 1-4 alkyl group, or may be methyl, ethyl, n-propyl, isopropyl Group, n-butyl, isobutyl, sec-butyl or tert-butyl, and may also be methyl, ethyl, n-propyl or isopropyl.
- the C 1-6 alkyl may be C 1-4 alkane Group, which can be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl, and can also be methyl, ethyl, n-propyl or isopropyl base.
- R 31 , R 33 and R 34 are independently C 1-6 alkyl substituted with one or more R 31-1 , the plurality of R 31, R 33 and R 34 may be two or three.
- R 31-1 is independently substituted by one or more R d15 , "a 4-10 membered heterocycloalkane containing 1-3 heteroatoms and one or more of O and N heteroatoms
- the “4-10 membered heterocycloalkyl group containing 1-3 heteroatoms and one or more of O and N” may be “containing 1-3 heteroatoms, Heteroatom is one or more of O and N 5-7 membered heterocycloalkyl", it can also be "a 5-7 membered heteroatom containing one heteroatom, heteroatom is one of O and N 5-7
- Cycloalkyl may also be tetrahydropyrrolyl or tetrahydropyrrol-2-yl.
- R 31-1 is independently substituted by one or more R d15 , "a 4-10 membered heterocycloalkane containing 1-3 heteroatoms and one or more of O and N heteroatoms
- the number of said multiple may be 2 or 3.
- the C 1-6 alkyl group may be a C 1-4 alkyl group, or may be methyl, ethyl, n-propyl, isopropyl Group, n-butyl, isobutyl, sec-butyl or tert-butyl, and may also be methyl.
- the halogen may be fluorine, chlorine, bromine or iodine, or may be fluorine.
- the C 1-6 alkyl may be C 1-4 alkyl, or may be methyl, ethyl, or n-propyl. , Isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl, and can also be methyl or ethyl.
- R 31 , R 33 and R 34 are independently C 1-6 alkyl substituted by one or more R 31-1 , said C 1 substituted by one or more R 31-1
- the -6 alkyl group can be
- the 4-12 membered heterocyclic ring containing 1-4 N atoms may be one containing 1-2 N atoms 6-9 membered heterocyclic ring, which can also be Its upper end is connected to R 2 .
- the C 1-6 alkyl group may be a C 1-4 alkyl group, or may be methyl, ethyl, n-propyl, isopropyl Group, n-butyl, isobutyl, sec-butyl or tert-butyl, and may also be methyl.
- the C 1-6 alkyl group may be a C 1-4 alkyl group or a methyl group.
- the plurality of R 4 may be 2 or 3.
- R 4 is 4-1 independently substituted with one or more R C 1-6 alkyl group
- said one or more R & lt 4-1 alkyl substituted with C 1- 6 can be Hydroxymethyl, cyanomethyl or Such as cyanomethyl or
- R 4 is 4-1 independently substituted with one or more R C 1-6 alkyl group
- said one or more R & lt 4-1 alkyl substituted with C 1- 6 can be
- R 4 is 4-1 independently substituted with one or more R C 1-6 alkyl group
- said one or more R & lt 4-1 alkyl substituted with C 1- 6 can be Hydroxymethyl or cyanomethyl.
- R 4 is 4-1 independently substituted with one or more R C 1-6 alkyl group
- said one or more R & lt 4-1 alkyl substituted with C 1- 6 can be Hydroxymethyl.
- R 4 is 4-1 independently substituted with one or more R C 1-6 alkyl group
- said one or more R & lt 4-1 alkyl substituted with C 1- 6 can be Cyanomethyl.
- said halogen may be fluorine, chlorine, bromine or iodine, or may be fluorine.
- the C 1-6 alkyl may be C 1-4 alkyl, or may be methyl, ethyl, or n-propyl , Isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl, and may also be methyl.
- said C 1-6 alkyl -C ( O) - in a C 1-6 alkoxy
- the group may be a C 1-4 alkyl group, or may be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl, and may also be methyl.
- said C 1-6 alkyl may be C 1-4 alkyl, and It can be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl, and it can also be methyl.
- the plurality may be two or three.
- the C 1-6 alkyl may be C 1-4 alkyl, or may be methyl, ethyl, or n-propyl , Isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl, and may also be methyl.
- R 10j and R 10k and the N connected to them together form a "4-10 membered heterocycloalkyl group containing 1-3 heteroatoms, and the heteroatoms are one or more of O and N"
- the “4-10 membered heterocycloalkyl group containing 1-3 heteroatoms, one or more of O and N” may be “containing 2 heteroatoms, heteroatoms are O and N’s 5-6 membered heterocycloalkyl", which can also be
- the R 2 can be CN
- the R 2 can be CN
- the R 2 can be any suitable R 2
- the R 2 can be any suitable R 2
- the oxygen-containing heterocyclic compound represented by formula I has any of the following structures:
- oxygen-containing heterocyclic compound represented by formula I is any of the following compounds:
- oxygen-containing heterocyclic compound represented by formula I is any of the following compounds:
- the present invention also provides a method for preparing the above-mentioned oxygen-containing heterocyclic compound represented by formula I, which is route one or route two:
- R 1 , R 2 , R 3 , R 4 , G, n, and Y have the same definitions as described above, X 1 is a leaving group (for example, OTf, Cl), etc., and Alk is an alkyl group (for example, C 1 -6 alkyl), PG is an amino protecting group (e.g. Boc, Cbz);
- R 1 , R 2 , R 3 , R 4 , G, n, and Y have the same definitions as described above, X 3 is a leaving group (for example, OTf, Cl), and PG is an amino protecting group (for example, Boc, Cbz).
- X 3 is a leaving group (for example, OTf, Cl)
- PG is an amino protecting group (for example, Boc, Cbz).
- aldehyde compound A1 is condensed with acetoacetate to obtain compound A2
- A2 is condensed with DMF-DMA to obtain compound A3
- A3 is reduced to A4
- A4 forms a ring after forming A5, A5
- the hydroxyl group is converted into a leaving group to obtain A6,
- A6 is converted to A7 by nucleophilic substitution or coupling,
- A7 is oxidized to obtain A8,
- A8 is further converted to A9, and A9 is deprotected, and further converted to A11.
- the detailed description of the second route can be as follows: Compound A5 is protected with Bn, C1 is oxidized to obtain C2, C2 is converted to C3 by nucleophilic substitution, C3 is converted to C4 by removing Bn protection, and the hydroxyl group in C4 is converted to a leaving group. The group gets C5, C5 is transformed into A9 through nucleophilic substitution or coupling, and A9 is deprotected, and further transformed into A11.
- the present invention also provides a compound represented by formula A5, A6, A7, A8, A9, A10, C1, C2, C3, C4 or C5;
- R 1 , R 3 , R 4 , G, Y and n are as defined above;
- X 1 and X 3 are independently leaving groups (for example, OTf, Cl), and PG is an amino protecting group (for example, Boc, Cbz).
- the compound represented by formula A5, A6, A7, A8, A9, A10, C1, C2, C3, C4 or C5 can be any of the following compounds:
- the present invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising substance A and pharmaceutical excipients; said substance A is the above-mentioned oxygen-containing heterocyclic compound represented by formula I, its pharmaceutically acceptable salt, and its solvent Compound, solvate of its pharmaceutically acceptable salt, its crystal form or its isotope compound.
- the present invention also provides an application of substance A in the preparation of RAS inhibitors, said substance A being the above-mentioned oxygen-containing heterocyclic compound represented by formula I, its pharmaceutically acceptable salt, and its solvate , The solvate of its pharmaceutically acceptable salt, its crystal form or its isotope compound.
- the RAS is, for example, KRAS G12C, HRAS G12C, or NRAS G12C mutation; for example, KRAS G12C.
- the present invention also provides the application of substance A in the preparation of medicines, which are used to treat or prevent RAS-mediated diseases;
- the substance A is the above-mentioned oxygen-containing heterocyclic compound represented by formula I, its pharmaceutically acceptable salt, its solvate, the solvate of its pharmaceutically acceptable salt, its crystal form or Isotope compounds.
- the RAS is, for example, KRAS G12C, HRAS G12C, or NRAS G12C mutation; for example, KRAS G12C.
- the RAS-mediated diseases are cancers.
- the cancer for example, colon cancer, pancreatic cancer, breast cancer, prostate cancer, lung cancer, brain cancer, ovarian cancer, cervical cancer, testicular cancer, kidney cancer, head or neck cancer, bone cancer, skin cancer, rectal cancer, liver cancer , Colon cancer, esophageal cancer, stomach cancer, pancreatic cancer, thyroid cancer, bladder cancer, lymphoma, leukemia, and melanoma.
- the present invention also provides an application of substance A in the preparation of medicines, which are used to treat or prevent cancer;
- the substance A is the above-mentioned oxygen-containing heterocyclic compound represented by formula I, its pharmaceutically acceptable salt, its solvate, the solvate of its pharmaceutically acceptable salt, its crystal form or Isotope compounds.
- the cancer for example, colon cancer, pancreatic cancer, breast cancer, prostate cancer, lung cancer, brain cancer, ovarian cancer, cervical cancer, testicular cancer, kidney cancer, head or neck cancer, bone cancer, skin cancer, rectal cancer, liver cancer , Colon cancer, esophageal cancer, stomach cancer, pancreatic cancer, thyroid cancer, bladder cancer, lymphoma, leukemia, and melanoma.
- the present invention also provides a method for inhibiting RAS, which comprises administering a therapeutically effective amount of substance A to a patient;
- the substance A is the above-mentioned oxygen-containing heterocyclic compound represented by formula I, its pharmaceutically acceptable salt, its solvate, the solvate of its pharmaceutically acceptable salt, its crystal form or Isotope compounds.
- the RAS is, for example, KRAS G12C, HRAS G12C, or NRAS G12C mutation; for example, KRAS G12C.
- the present invention also provides a method for treating or preventing RAS-mediated diseases, which comprises administering to a patient a therapeutically effective amount of substance A;
- the substance A is the above-mentioned oxygen-containing heterocyclic compound represented by formula I, its pharmaceutically acceptable salt, its solvate, the solvate of its pharmaceutically acceptable salt, its crystal form or Isotope compounds.
- the RAS is, for example, KRAS G12C, HRAS G12C, or NRAS G12C mutation; for example, KRAS G12C.
- the RAS-mediated diseases are cancers.
- the cancer for example, colon cancer, pancreatic cancer, breast cancer, prostate cancer, lung cancer, brain cancer, ovarian cancer, cervical cancer, testicular cancer, kidney cancer, head or neck cancer, bone cancer, skin cancer, rectal cancer, liver cancer , Colon cancer, esophageal cancer, stomach cancer, pancreatic cancer, thyroid cancer, bladder cancer, lymphoma, leukemia, and melanoma.
- the present invention also provides a method for treating or preventing cancer, which comprises administering to a patient a therapeutically effective amount of substance A;
- the substance A is the above-mentioned oxygen-containing heterocyclic compound represented by formula I, its pharmaceutically acceptable salt, its solvate, the solvate of its pharmaceutically acceptable salt, its crystal form or Isotope compounds.
- the cancer for example, colon cancer, pancreatic cancer, breast cancer, prostate cancer, lung cancer, brain cancer, ovarian cancer, cervical cancer, testicular cancer, kidney cancer, head or neck cancer, bone cancer, skin cancer, rectal cancer, liver cancer , Colon cancer, esophageal cancer, stomach cancer, pancreatic cancer, thyroid cancer, bladder cancer, lymphoma, leukemia, and melanoma.
- pharmaceutically acceptable salt refers to a salt prepared from a compound of the present invention with a relatively non-toxic, pharmaceutically acceptable acid or base.
- the compound of the present invention contains a relatively acidic functional group, it can be obtained by contacting the neutral form of the compound with a sufficient amount of a pharmaceutically acceptable base in a pure solution or a suitable inert solvent.
- Pharmaceutically acceptable base addition salts include, but are not limited to: lithium salt, sodium salt, potassium salt, calcium salt, aluminum salt, magnesium salt, zinc salt, bismuth salt, ammonium salt, and diethanolamine salt.
- the acid addition can be obtained by contacting the neutral form of the compound with a sufficient amount of a pharmaceutically acceptable acid in a pure solution or a suitable inert solvent.
- a pharmaceutically acceptable acid include inorganic acids, and the inorganic acids include, but are not limited to: hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, carbonic acid, phosphoric acid, phosphorous acid, sulfuric acid, and the like.
- the pharmaceutically acceptable acids include organic acids, including but not limited to: acetic acid, propionic acid, oxalic acid, isobutyric acid, maleic acid, malonic acid, benzoic acid, succinic acid, suberic acid , Fumaric acid, lactic acid, mandelic acid, phthalic acid, benzenesulfonic acid, p-toluenesulfonic acid, citric acid, salicylic acid, tartaric acid, methanesulfonic acid, isonicotinic acid, acid citric acid, oleic acid , Tannic acid, pantothenic acid, hydrogen tartrate, ascorbic acid, gentisic acid, fumaric acid, gluconic acid, sugar acid, formic acid, ethanesulfonic acid, pamoic acid (i.e.
- solvate refers to a substance formed by combining the compound of the present invention with a stoichiometric or non-stoichiometric solvent.
- the solvent molecules in the solvate can exist in an ordered or non-ordered arrangement.
- the solvents include but are not limited to: water, methanol, ethanol and the like.
- pharmaceutically acceptable salt and solvate in the term “pharmaceutically acceptable salt solvate” are as described above, which means that the compound of the present invention is combined with 1, and relatively non-toxic, pharmaceutically acceptable 2.
- solvate of a pharmaceutically acceptable salt includes, but is not limited to, the hydrochloric acid monohydrate of the compound of the present invention.
- stereoisomer refers to the isomers caused by the same order of interconnection of atoms or atomic groups in the molecule, but different spatial arrangements, such as cis-trans isomers, optical isomers or atropisomers. These stereoisomers can be separated, purified and enriched by asymmetric synthesis methods or chiral separation methods (including but not limited to thin layer chromatography, rotation chromatography, column chromatography, gas chromatography, high pressure liquid chromatography, etc.), and can also be obtained by It can be obtained by chiral resolution by forming bonds with other chiral compounds (chemical bonding, etc.) or salting (physical bonding, etc.).
- tautomer refers to an isomer of a functional group resulting from the rapid movement of an atom in a molecule at two positions. For example, acetone and 1-propene-2-ol can be converted into each other by the rapid movement of hydrogen atoms on oxygen and ⁇ -carbon.
- crystal form means that the ions or molecules are arranged strictly and periodically in a three-dimensional space in a certain way, and have the regularity of periodic recurrence at a certain distance; due to the above-mentioned periodic arrangement, there may be multiple Crystal form, that is, polymorphism.
- isotopic compound refers to the substitution of one or more atoms in the compound by one or more atoms having a specific atomic mass or mass number.
- isotopes that can be incorporated into the compounds of the present invention include, but are not limited to, isotopes of hydrogen, carbon, nitrogen, oxygen, fluorine, sulfur, and chlorine (e.g., 2H, 3H, 13C, 14C, 15N, 18O, 17O, 18F, 35S, and 36Cl).
- the isotopic compounds of the present invention can generally be prepared by substituting isotopically-labeled reagents for non-isotopically-labeled reagents according to the methods described herein.
- variable such as R 1-6
- the definition in each position of the variable has nothing to do with the definition in the other positions, and their meanings are independent of each other and do not affect each other. Therefore, if a group is substituted by 1, 2, or 3 R 1-6 groups, that is, the group may be substituted by up to 3 R 1-6 , the definition of R 1-6 at this position The definition of R 1-6 is independent of the other positions. In addition, combinations of substituents and/or variables are only allowed if the combination results in a stable compound.
- halogen refers to fluorine, chlorine, bromine or iodine.
- alkyl refers to a straight or branched chain alkyl group having the specified number of carbon atoms.
- alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl and It is similar to an alkyl group.
- alkoxy refers to the group -OR X , where R X is an alkyl group as defined above.
- cycloalkyl refers to a saturated monocyclic alkyl group, preferably a saturated monocyclic alkyl group having 3-7 ring carbon atoms, more preferably 3-6 carbon atoms, such as cyclopropyl, cyclobutyl, Cyclopentyl or cyclohexyl.
- heterocycloalkyl refers to a saturated monocyclic group with heteroatoms, preferably a 3-7 membered saturated monocyclic group containing 1, 2, or 3 ring heteroatoms independently selected from N, O or S ring.
- heterocycloalkyl groups are: pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothienyl, tetrahydropyridyl, tetrahydropyrrolyl, azetidinyl, thiazolidinyl, oxazolidinyl , Piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, azepanyl, diazacycloheptanyl, oxazepanyl, etc.
- Preferred heterocyclic groups are morpholin-4-yl, piperidin-1-yl, pyrrolidin-1-yl, thiomorpholin-4
- saturated heterocyclic ring refers to a saturated cyclic group with heteroatoms, which may be a monocyclic ring, a bridged ring or a spiro ring.
- the monocyclic "saturated heterocyclic ring” is the above-mentioned “heterocycloalkyl”.
- partially saturated heterocyclic ring refers to a partially saturated cyclic group with heteroatoms, which is neither fully saturated nor aromatic, and can be a monocyclic ring, a bridged ring or a spiro ring.
- Examples of the "partially saturated heterocyclic ring” are: pyran ring, 1,2,5,6-tetrahydropyridine.
- aryl refers to an aromatic group composed of carbon atoms, and each ring is aromatic. For example, phenyl or naphthyl.
- heteroaryl refers to an aromatic group containing heteroatoms, each ring having aromaticity; preferably containing 1, 2, or 3 aromatic 5-6 membered monomers independently selected from nitrogen, oxygen or sulfur Ring or 9-10 membered bicyclic ring, such as furyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, thienyl, isoxazolyl, oxazolyl, diazolyl, imidazolyl, pyrrolyl, pyrazolyl , Triazolyl, tetrazolyl, thiazolyl, isothiazolyl, thiadiazolyl, benzimidazolyl, indolyl, indazolyl, benzothiazolyl, benzisothiazolyl, benzoxazolyl, Benzisoazolyl, quinolinyl, isoquinolinyl and the like.
- pharmaceutical excipients refers to excipients and additives used in the production of drugs and formulating prescriptions, and are all substances contained in pharmaceutical preparations except for active ingredients. Please refer to the Fourth Edition of the Pharmacopoeia of the People's Republic of China (2015 Edition), or Handbook of Pharmaceutical Excipients (Raymond C Rowe, 2009 Sixth Edition)
- treatment refers to therapeutic therapy.
- treatment refers to: (1) alleviating one or more biological manifestations of the disease or disease, (2) interfering with (a) one or more points in the biological cascade causing or causing the disease, or (b) ) One or more biological manifestations of the disorder, (3) Improve one or more symptoms, effects or side effects related to the disorder, or one or more symptoms, effects or side effects related to the disorder or its treatment, Or (4) to slow down the development of the disease or one or more biological manifestations of the disease.
- prevention refers to a reduction in the risk of acquiring or developing a disease or disorder.
- terapéuticaally effective amount refers to an amount of a compound that is sufficient to effectively treat the diseases or conditions described herein when administered to a patient.
- the “therapeutically effective amount” will vary according to the compound, the condition and its severity, and the age of the patient to be treated, but can be adjusted by those skilled in the art as needed.
- patient refers to any animal that is about to or has received administration of the compound or composition according to an embodiment of the present invention, mammals are preferred, and humans are preferred.
- mammal includes any mammal. Examples of mammals include, but are not limited to, cows, horses, sheep, pigs, cats, dogs, mice, rats, rabbits, guinea pigs, monkeys, humans, etc., with humans being the most preferred.
- the reagents and starting materials used in the present invention are all commercially available.
- the room temperature refers to the ambient temperature, which is 10°C to 35°C.
- the positive progress effect of the present invention is that the oxygen-containing heterocyclic compound is expected to treat and/or prevent various diseases mediated by Ras.
- room temperature refers to ambient temperature, which is 10°C to 35°C. Overnight means 8-15 hours. Reflux refers to the solvent reflux temperature under normal pressure.
- reaction was quenched by adding saturated ammonium chloride solution (100mL), extracted with ethyl acetate (100mL*3), the organic phase was washed with saturated brine (100mL), dried over anhydrous sodium sulfate, filtered and concentrated to obtain the crude product.
- DIPEA 75 ⁇ L, 0.45 mmol
- acryloyl chloride 25 ⁇ L, 0.23 mmol
- compound 3 (170 mg) was synthesized, and compound 3-1 (40 mg, 24%) was obtained as white solid by chiral resolution and purification, and compound 3-2 (20 mg, 12%) was obtained as white solid.
- compound 4-h (770mg, 2.59mmol) was dissolved in THF (60mL), and under nitrogen at -78°C, a solution of lithium tri-sec-butylborohydride in tetrahydrofuran (1M, 2.6mL, 2.6mmol). After the addition, the mixture was stirred at -78°C for 1 hour, then saturated ammonium chloride solution (50mL) was added to quench the reaction, extracted with ethyl acetate (100mL*2), and washed with saturated brine (100mL*2). Anhydrous sodium sulfate was dried, filtered, and concentrated to obtain a crude product.
- compound 4 (140mg) was synthesized. After chiral resolution and purification, compound 4-1 (30mg, 21% yield) was obtained as white solid, and compound 4-2 (40mg, 29% yield) was white solid.
Abstract
Description
Claims (20)
- 一种如式I所示的含氧杂环化合物、其药学上可接受的盐、其溶剂合物、其药学上可接受的盐的溶剂合物、其晶型、其立体异构体、其互变异构体或其同位素化合物,其特征在于:其中,R 1为C 6-20芳基、“含1-4个杂原子,杂原子为O、S和N中的一种或多种的5-12元杂芳基”、被一个或多个R 1-6取代的C 6-20芳基、或、被一个或多个R 1-7取代的“含1-4个杂原子,杂原子为O、S和N中的一种或多种的5-12元杂芳基”;R 1-6和R 1-7独立地为卤素、羟基、-C(=O)R 65、-NR 63R 64、-C(=O)OR 66、-C(=O)NR 69R 610、C 1-6烷基、C 1-6烷氧基、C 3-10环烷基、“含1个或2个杂原子,杂原子为O和N中的一种或多种的5-7元杂环烷基”、C 6-20芳基、“含1个或2个杂原子,杂原子为O和N中的一种或多种的5-7元杂芳基”、被一个或多个R 1-6-1取代的C 1-6烷基、被一个或多个R 1-6-2取代的C 1-6烷氧基、被一个或多个R 1-6-3取代的C 3- 10环烷基、被一个或多个R 1-6-4取代的“含1个或2个杂原子,杂原子为O和N中的一种或多种的5-7元杂环烷基”、被一个或多个R 1-6-5取代的C 6-20芳基、或、被一个或多个R 1-6-6取代的“含1个或2个杂原子,杂原子为O和N中的一种或多种的5-7元杂芳基”;R 1-6-1、R 1-6-2、R 1-6-3、R 1-6-4、R 1-6-5和R 1-6-6独立地为氰基、卤素、羟基、C 1-6烷氧基、C 1-6烷基、-C(=O)R 65-2、-NR 63-2R 64-2、-C(=O)OR 66-2、或、-C(=O)NR 69-2R 610-2;R 65、R 65-2、R 63、R 63-2、R 64、R 64-2、R 66、R 66-2、R 69、R 69-2、R 610和R 610-2独立地为氢或C 1-6烷基;m为0、1或2;R 5独立地为C 1-6烷基;R 3为-OR 31、-SR 32或-NR 33R 34;R 31、R 32和R 34独立地为被一个或多个R 31-1取代的C 1-6烷基;R 33独立地为H、C 1-6烷基、或被一个或多个R 31-1取代的C 1-6烷基;R 31-1独立地为C 3-10环烷基、“含1-3个杂原子,杂原子为O和N中的一种或多种的4-10元杂环烷基”、被一个或多个R d16取代的C 3-10环烷基、被一个或多个R d15取代的“含1-3个杂原子,杂原子为O和N中的一种或多种的4-10元杂环烷基”、-OR d、-SR d1、-NR e1R e2、或、-C(=O)NR e3R e4;R d15和R d16独立地为C 1-6烷基、被一个或多个R 1-8-1取代的C 1-6烷基、羟基、C 1-6烷氧基、卤素、-NR e5R e6或-C(=O)NR e7R e8;R d、R d1、R e1、R e2、R e3和R e4独立地为氢、C 1-6烷基、C 3-10环烷基、“含1-3个杂原子,杂原子为O和N中的一种或多种的4-10元杂环烷基”、或、被一个或多个R 1-8-2取代的C 1-6烷基;R 1-8-1和R 1-8-2独立地为氰基、卤素、羟基、C 1-6烷氧基、-C(=O)R e9、-NR e10R e11、-C(=O)OR e12、或、-C(=O)NR e13R e14;R e5、R e6、R e7、R e8、R e9、R e10、R e11、R e12、R e13和R e14独立地为氢或C 1-6烷基;环Y为含1-4个N原子的4-12元杂环;所述的杂环为饱和杂环或部分饱和杂环;所述的杂环为单环、桥环或螺环;G为N、C或CH;n为0、1、2或3;R 4独立地为C 1-6烷基、被一个或多个R 4-1取代的C 1-6烷基、氧代、-C(=O)OR 4a或-C(=O)NR 4bR 4c;R 4-1独立地为卤素、氰基、羟基、C 1-6烷氧基、-NR 4iR 4j、-C(=O)OR 4d或-C(=O)NR 4eR 4f;R 4d、R 4e、R 4f、R 4i和R 4j独立地为氢或C 1-6烷基;R 4a、R 4b和R 4c独立地为氢或C 1-6烷基;R 2为CN、-C(=O)-C(R a)=C(R b)(R f)、-C(=O)-C≡CR f、-S(=O) 2-C(R a)=C(R b)(R f)或-S(=O) 2-C≡CR f;R a独立地为氢、氘、卤素或C 1-6烷基;R b和R f独立地为氢、氘、C 1-6烷基、C 1-6烷基-C(=O)-、或、被一个或多个R b-1取代的C 1-6烷基;R b-1独立地为卤素、羟基、C 1-6烷氧基、或、-NR 10jR 10k;R 10j和R 10k独立地为氢或C 1-6烷基,或者,R 10j、R 10k以及与之相连的N共同形成“含1-3个杂原子,杂原子为O和N中的一种或多种的4-10元杂环烷基”。
- 如权利要求1所述的如式I所示的含氧杂环化合物、其药学上可接受的盐、其溶剂合物、其药学上可接受的盐的溶剂合物、其晶型、其立体异构体、其互变异构体或其同位素化合物,其特征在于,R 1为C 6-20芳基、“含1-4个杂原子,杂原子为O、S和N中的一种或多种的5-12元杂芳基”、被一个或多个R 1-6取代的C 6-20芳基、或、被一个或多个R 1-7取代的“含1-4个杂原子,杂原子为O、S和N中的一种或多种的5-12元杂芳基”;R 1-6和R 1-7独立地为卤素、羟基、C 1-6烷基、C 1-6烷氧基、C 3-10环烷基、被一个或多个R 1-6-1取代的C 1-6烷基、或、被一个或多个R 1-6-2取代的C 1-6烷氧基;R 1-6-1和R 1- 6-2独立地为卤素;和/或,m为0;和/或,R 3为-OR 31或-NR 33R 34;R 31、R 33和R 34独立地为被一个或多个R 31-1取代的C 1-6烷基;R 31- 1独立地为被一个或多个R d15取代的“含1-3个杂原子,杂原子为O和N中的一种或多种的5-7元杂环烷基”、或、-NR e1R e2;R d15独立地为C 1-6烷基、被一个或多个R 1-8-1取代的C 1-6烷基、羟基、C 1-6烷氧基、卤素、-NR e5R e6或-C(=O)NR e7R e8;R 1-8-1独立地为卤素;R e5、R e6、R e7和R e8独立地为氢或C 1-6烷基;R e1和R e2独立地为C 1-6烷基;和/或,环Y为含1-4个N原子的4-12元杂环;所述的杂环为饱和杂环或部分饱和杂环;所述的杂环为单环或螺环;G为N、C或CH;和/或,n为0或1;R 4独立地为C 1-6烷基、或、被一个或多个R 4-1取代的C 1-6烷基;R 4-1独立地为氰基;和/或,R 2为-C(=O)-C(R a)=C(R b)(R f)、-C(=O)-C≡C-Me或、-S(=O) 2-C(R a)=C(R b)(R f);R a独立地为氢或卤素;R b和R f独立地为氢、C 1-6烷基、或、被一个或多个R b-1取代的C 1-6烷基;R b-1独立地为卤素、羟基、C 1-6烷氧基、或、-NR 10jR 10k;R 10j和R 10k独立地为氢或C 1-6烷基,或者,R 10j、R 10k以及与之相连的N共同形成“含1-3个杂原子,杂原子为O和N中的一种或多种的4-6元杂环烷基”。
- 如权利要求2所述的如式I所示的含氧杂环化合物、其药学上可接受的盐、其溶剂合物、其药学上可接受的盐的溶剂合物、其晶型、其立体异构体、其互变异构体或其同位素化合物,其特征在于,R 1为C 6-20芳基、或、被一个或多个R 1-6取代的C 6-20芳基;R 1-6独立地为卤素、C 1-6烷基、或、被一个或多个R 1-6-1取代的C 1-6烷基;R 1-6-1独立地为卤素;和/或,R 3为-OR 31或-NR 33R 34;R 31、R 33和R 34独立地为被一个或多个R 31-1取代的C 1-6烷基;R 31- 1独立地为被一个或多个R d15取代的“含1-3个杂原子,杂原子为O和N中的一种或多种的5-7元杂环烷基”、或、-NR e1R e2;R e1、R e2和R d15独立地为C 1-6烷基;和/或,环Y为含1-4个N原子的4-12元杂环;所述的杂环为饱和杂环或部分饱和杂环;所述的杂环为单环;G为N;和/或,n为0或1;R 4独立地为C 1-6烷基、或、被一个或多个R 4-1取代的C 1-6烷基;R 4-1独立地为氰基;和/或,R 2为-C(=O)-C(R a)=C(R b)(R f);R a独立地为氢或卤素;R b和R f独立地为氢或C 1-6烷基。
- 如权利要求1所述的如式I所示的含氧杂环化合物、其药学上可接受的盐、其溶剂合物、其药学上可接受的盐的溶剂合物、其晶型、其立体异构体、其互变异构体或其同位素化合物,其特征在于,R 1为C 6-20芳基、“含1-4个杂原子,杂原子为O、S和N中的一种或多种的5-12元杂芳基”、被一个或多个R 1-6取代的C 6-20芳基、或、被一个或多个R 1-7取代的“含1-4个杂原子,杂原子为O、S和N中的一种或多种的5-12元杂芳基”;R 1-6和R 1-7独立地为卤素、C 1-6烷基、或、被一个或多个R 1-6-1取代的C 1-6烷基;R 1-6-1独立地为卤素;和/或,R 3为-OR 31、-SR 32或-NR 33R 34;R 31、R 32和R 34独立地为被一个或多个R 31-1取代的C 1-6烷基;R 33独立地为H、C 1-6烷基、或被一个或多个R 31-1取代的C 1-6烷基;R 31-1独立地为被一个或多个R d15取代的“含1-3个杂原子,杂原子为O和N中的一种或多种的5-7元杂环烷基”、或、-NR e1R e2;R d15独立地为C 1-6烷基或卤素;R e1和R e2独立地为C 1-6烷基;和/或,n为0或1;R 4独立地为C 1-6烷基、或、被一个或多个R 4-1取代的C 1-6烷基;R 4-1独立地为羟基、氰基、或、-C(=O)NR 4eR 4f;R 4e和R 4f独立地为氢或C 1-6烷基;和/或,R 2为CN、-C(=O)-C(R a)=C(R b)(R f)、-C(=O)-C≡C-Me或、-S(=O) 2-C(R a)=C(R b)(R f);R a独立地为氢或卤素;R b和R f独立地为氢、C 1-6烷基、C 1-6烷基-C(=O)-、或、被一个或多个R b-1取代的C 1- 6烷基;R b-1独立地为-NR 10jR 10k;R 10j和R 10k独立地为氢或C 1-6烷基,或者,R 10j、R 10k以及与之相连的N共同形成“含1-3个杂原子,杂原子为O和N中的一种或多种的4-6元杂环烷基”。
- 如权利要求1所述的如式I所示的含氧杂环化合物、其药学上可接受的盐、其溶剂合物、其药学上可接受的盐的溶剂合物、其晶型、其立体异构体、其互变异构体或其同位素化合物,其特征在于,R 3为-OR 31或-NR 33R 34;R 31、R 33和R 34独立地为被一个或多个R 31-1取代的C 1-6烷基;R 31-1独立地为被一个或多个R d15取代的“含1-3个杂原子,杂原子为O和N中的一种或多种的5-7元杂环烷基”、或、-NR e1R e2;R d15独立地为C 1-6烷基或卤素;R e1和R e2独立地为C 1-6烷基;和/或,n为0或1;R 4独立地为C 1-6烷基、或、被一个或多个R 4-1取代的C 1-6烷基;R 4-1独立地为羟基或氰基;和/或,R 2为-C(=O)-C(R a)=C(R b)(R f)、-C(=O)-C≡C-Me或、-S(=O) 2-C(R a)=C(R b)(R f);R a独立地为氢或卤素;R b和R f独立地为氢、C 1-6烷基、或、被一个或多个R b-1取代的C 1-6烷基;R b-1独立地为-NR 10jR 10k;R 10j和R 10k独立地为氢或C 1-6烷基,或者,R 10j、R 10k以及与之相连的N共同形成“含1-3个杂原子,杂原子为O和N中的一种或多种的4-6元杂环烷基”。
- 如权利要求1所述的如式I所示的含氧杂环化合物、其药学上可接受的盐、其溶剂合物、其药学上可接受的盐的溶剂合物、其晶型、其立体异构体、其互变异构体或其同位素化合物,其特征在于,所述的如式I所示的含氧杂环化合物的定义为方案1、方案2、方案3、方案4、方案5、方案6或方案7:方案1:R 1为C 6-20芳基、“含1-4个杂原子,杂原子为O、S和N中的一种或多种的5-12元杂芳基”、被一个或多个R 1-6取代的C 6-20芳基、或、被一个或多个R 1-7取代的“含1-4个杂原子,杂原子为O、S和N中的一种或多种的5-12元杂芳基”;R 1-6和R 1-7独立地为卤素、羟基、C 1-6烷基、C 1-6烷氧基、C 3-10环烷基、被一个或多个R 1-6-1取代的C 1-6烷基、或、被一个或多个R 1-6-2取代的C 1-6烷氧基;R 1-6-1和R 1-6-2独立地为卤素;m为0;R 3为-OR 31或-NR 33R 34;R 31、R 33和R 34独立地为被一个或多个R 31-1取代的C 1-6烷基;R 31-1独立地为被一个或多个R d15取代的“含1-3个杂原子,杂原子为O和N中的一种或多种的5-7元杂环烷基”、或、-NR e1R e2;R d15独立地为C 1-6烷基、被一个或多个R 1-8-1取代的C 1-6烷基、羟基、C 1-6烷氧基、卤素、-NR e5R e6或-C(=O)NR e7R e8;R 1-8-1独立地为卤素;R e5、R e6、R e7和R e8独立地为氢或C 1-6烷基;R e1和R e2独立地为C 1-6烷基;环Y为含1-4个N原子的4-12元杂环;所述的杂环为饱和杂环或部分饱和杂环;所述的杂环为单环或螺环;G为N、C或CH;n为0或1;R 4独立地为C 1-6烷基、或、被一个或多个R 4-1取代的C 1-6烷基;R 4-1独立地为氰基;R 2为-C(=O)-C(R a)=C(R b)(R f)、-C(=O)-C≡C-Me或、-S(=O) 2-C(R a)=C(R b)(R f);R a独立地为氢或卤素;R b和R f独立地为氢、C 1-6烷基、或、被一个或多个R b-1取代的C 1-6烷基;R b-1独立地为卤素、羟基、C 1-6烷氧基、或、-NR 10jR 10k;R 10j和R 10k独立地为氢或C 1-6烷基,或者,R 10j、R 10k以及与之相连的N共同形成“含1-3个杂原子,杂原子为O和N中的一种或多种的4-6元杂环烷基”;方案2:R 1为C 6-20芳基、或、被一个或多个R 1-6取代的C 6-20芳基;R 1-6独立地为卤素、C 1-6烷基、或、被一个或多个R 1-6-1取代的C 1-6烷基;R 1-6-1独立地为卤素;m为0;R 3为-OR 31或-NR 33R 34;R 31、R 33和R 34独立地为被一个或多个R 31-1取代的C 1-6烷基;R 31-1独立地为被一个或多个R d15取代的“含1-3个杂原子,杂原子为O和N中的一种或多种的5-7元杂环烷基”、或、-NR e1R e2;R e1、R e2和R d15独立地为C 1-6烷基;环Y为含1-4个N原子的4-12元杂环;所述的杂环为饱和杂环或部分饱和杂环;所述的杂环为单环;G为N;n为0或1;R 4独立地为C 1-6烷基、或、被一个或多个R 4-1取代的C 1-6烷基;R 4-1独立地为氰基;R 2为-C(=O)-C(R a)=C(R b)(R f);R a独立地为氢或卤素;R b和R f独立地为氢或C 1-6烷基;方案3:R 1为C 6-20芳基、“含1-4个杂原子,杂原子为O、S和N中的一种或多种的5-12元杂芳基”、被一个或多个R 1-6取代的C 6-20芳基、或、被一个或多个R 1-7取代的“含1-4个杂原子,杂原子为O、S和N中的一种或多种的5-12元杂芳基”;R 1-6和R 1-7独立地为卤素、羟基、C 1-6烷基、C 1-6烷氧基、C 3-10环烷基、被一个或多个R 1-6-1取代的C 1-6烷基、或、被一个或多个R 1-6-2取代的C 1-6烷氧基;R 1-6-1和R 1-6-2独立地为卤素;m为0;R 3为-OR 31或-NR 33R 34;R 31、R 33和R 34独立地为被一个或多个R 31-1取代的C 1-6烷基;R 31-1独立地为被一个或多个R d15取代的“含1-3个杂原子,杂原子为O和N中的一种或多种的5-7元杂环烷基”、或、-NR e1R e2;R d15独立地为C 1-6烷基、被一个或多个R 1-8-1取代的C 1-6烷基、羟基、C 1-6烷氧基、卤素、-NR e5R e6或-C(=O)NR e7R e8;R 1-8-1独立地为卤素;R e5、R e6、R e7和R e8独立地为氢或C 1-6烷基;R e1和R e2独立地为C 1-6烷基;环Y为含1-4个N原子的4-12元杂环;所述的杂环为饱和杂环或部分饱和杂环;所述的杂环为单环或螺环;G为N、C或CH;n为0或1;R 4独立地为C 1-6烷基、或、被一个或多个R 4-1取代的C 1-6烷基;R 4-1独立地为氰基或羟基;R 2为-C(=O)-C(R a)=C(R b)(R f)、-C(=O)-C≡C-Me或、-S(=O) 2-C(R a)=C(R b)(R f);R a独立地为氢或卤素;R b和R f独立地为氢、C 1-6烷基、或、被一个或多个R b-1取代的C 1-6烷基;R b-1独立地为卤素、羟基、C 1-6烷氧基、或、-NR 10jR 10k;R 10j和R 10k独立地为氢或C 1-6烷基,或者,R 10j、R 10k以及与之相连的N共同形成“含1-3个杂原子,杂原子为O和N中的一种或多种的4-6元杂环烷基”;方案4:R 1为C 6-20芳基、或、被一个或多个R 1-6取代的C 6-20芳基;R 1-6独立地为卤素、C 1-6烷基、或、被一个或多个R 1-6-1取代的C 1-6烷基;R 1-6-1独立地为卤素;m为0;R 3为-OR 31或-NR 33R 34;R 31、R 33和R 34独立地为被一个或多个R 31-1取代的C 1-6烷基;R 31-1独立地为被一个或多个R d15取代的“含1-3个杂原子,杂原子为O和N中的一种或多种的5-7元杂环烷基”、或、-NR e1R e2;R d15独立地为C 1-6烷基或卤素;R e1和R e2独立地为C 1-6烷基;环Y为含1-4个N原子的4-12元杂环;所述的杂环为饱和杂环或部分饱和杂环;所述的杂环为单环;G为N;n为0或1;R 4独立地为C 1-6烷基、或、被一个或多个R 4-1取代的C 1-6烷基;R 4-1独立地为氰基;R 2为-C(=O)-C(R a)=C(R b)(R f);R a独立地为氢或卤素;R b和R f独立地为氢或C 1-6烷基、或、被一个或多个R b-1取代的C 1-6烷基;R b-1独立地为-NR 10jR 10k;R 10j和R 10k独立地为氢或C 1-6烷基,或者,R 10j、R 10k以及与之相连的N共同形成“含1-3个杂原子,杂原子为O和N中的一种或多种的4-10元杂环烷基”;方案5:R 1为C 6-20芳基、“含1-4个杂原子,杂原子为O、S和N中的一种或多种的5-12元杂芳基”、被一个或多个R 1-6取代的C 6-20芳基、或、被一个或多个R 1-7取代的“含1-4个杂原子,杂原子为O、S和N中的一种或多种的5-12元杂芳基”;R 1-6和R 1-7独立地为卤素、羟基、-C(=O)R 65、-NR 63R 64、-C(=O)OR 66、-C(=O)NR 69R 610、C 1-6烷基、C 1-6烷氧基、C 3-10环烷基、“含1个或2个杂原子,杂原子为O和N中的一种或多种的5-7元杂环烷基”、C 6-20芳基、“含1个或2个杂原子,杂原子为O和N中的一种或多种的5-7元杂芳基”、被一个或多个R 1-6-1取代的C 1-6烷基、被一个或多个R 1-6-2取代的C 1-6烷氧基、被一个或多个R 1-6-3取代的C 3- 10环烷基、被一个或多个R 1-6-4取代的“含1个或2个杂原子,杂原子为O和N中的一种或多种的5-7元杂环烷基”、被一个或多个R 1-6-5取代的C 6-20芳基、或、被一个或多个R 1-6-6取代的“含1个或2个杂原子,杂原子为O和N中的一种或多种的5-7元杂芳基”;R 1-6-1、R 1-6-2、R 1-6-3、R 1-6-4、R 1-6-5和R 1-6-6独立地为氰基、卤素、羟基、C 1-6烷氧基、C 1-6烷基、-C(=O)R 65-2、-NR 63-2R 64-2、-C(=O)OR 66-2、或、-C(=O)NR 69-2R 610-2;R 65、R 65-2、R 63、R 63-2、R 64、R 64-2、R 66、R 66-2、R 69、R 69-2、R 610和R 610-2独立地为氢或C 1-6烷基;m为0、1或2;R 5独立地为C 1-6烷基;R 3为-OR 31、-SR 32或-NR 33R 34;R 31、R 32、R 33和R 34独立地为被一个或多个R 31-1取代的C 1-6烷基;R 31-1独立地为C 3-10环烷基、“含1-3个杂原子,杂原子为O和N中的一种或多种的4-10元杂环烷基”、被一个或多个R d16取代的C 3-10环烷基、被一个或多个R d15取代的“含1-3个杂原子,杂原子为O和N中的一种或多种的4-10元杂环烷基”、-OR d、-SR d1、-NR e1R e2、或、-C(=O)NR e3R e4;R d15和R d16独立地为C 1-6烷基、被一个或多个R 1-8-1取代的C 1-6烷基、羟基、C 1-6烷氧基、卤素、-NR e5R e6或-C(=O)NR e7R e8;R d、R d1、R e1、R e2、R e3和R e4独立地为氢、C 1-6烷基、C 3-10环烷基、“含1-3个杂原子,杂原子为O和N中的一种或多种的4-10元杂环烷基”、或、被一个或多个R 1-8-2取代的C 1-6烷基;R 1-8-1和R 1-8-2独立地为氰基、卤素、羟基、C 1-6烷氧基、-C(=O)R e9、-NR e10R e11、-C(=O)OR e12、或、-C(=O)NR e13R e14;R e5、R e6、R e7、R e8、R e9、R e10、R e11、R e12、R e13和R e14独立地为氢或C 1-6烷基;环Y为含1-4个N原子的4-12元杂环;所述的杂环为饱和杂环或部分饱和杂环;所述的杂环为单环、桥环或螺环;G为N、C或CH;n为0、1、2或3;R 4独立地为C 1-6烷基、被一个或多个R 4-1取代的C 1-6烷基、氧代、-C(=O)OR 4a或-C(=O)NR 4bR 4c;R 4-1独立地为卤素、氰基、羟基、C 1-6烷氧基、-NR 4iR 4j、-C(=O)OR 4d或-C(=O)NR 4eR 4f;R 4d、R 4e、R 4f、R 4i和R 4j独立地为氢或C 1-6烷基;R 4a、R 4b和R 4c独立地为氢或C 1-6烷基;R 2为-C(=O)-C(R a)=C(R b)(R f)、-C(=O)-C≡CR f、-S(=O) 2-C(R a)=C(R b)(R f)或-S(=O) 2-C≡CR f;R a独立地为氢、氘、卤素或C 1-6烷基;R b和R f独立地为氢、氘、C 1-6烷基、或、被一个或多个R b-1取代的C 1-6烷基;R b-1独立地为卤素、羟基、C 1-6烷氧基、或、-NR 10jR 10k;R 10j和R 10k独立地为氢或C 1-6烷基,或者,R 10j、R 10k以及与之相连的N共同形成“含1-3个杂原子,杂原子为O和N中的一种或多种的4-10元杂环烷基”;方案6:R 1为C 6-20芳基、“含1-4个杂原子,杂原子为O、S和N中的一种或多种的5-12元杂芳基”、被一个或多个R 1-6取代的C 6-20芳基、或、被一个或多个R 1-7取代的“含1-4个杂原子,杂原子为O、S和N中的一种或多种的5-12元杂芳基”;R 1-6和R 1-7独立地为卤素、羟基、C 1-6烷基、C 1-6烷氧基、C 3-10环烷基、被一个或多个R 1-6-1取代的C 1-6烷基、或、被一个或多个R 1-6-2取代的C 1-6烷氧基;R 1-6-1和R 1-6-2独立地为卤素;m为0;R 3为-OR 31、-SR 32或-NR 33R 34;R 31、R 32和R 34独立地为被一个或多个R 31-1取代的C 1-6烷基;R 33独立地为H、C 1-6烷基或被一个或多个R 31-1取代的C 1-6烷基;R 31-1独立地为被一个或多个R d15取代的“含1-3个杂原子,杂原子为O和N中的一种或多种的5-7元杂环烷基”、或、-NR e1R e2;R d15独立地为C 1-6烷基或卤素;R e1和R e2独立地为C 1-6烷基;环Y为含1-4个N原子的4-12元杂环;所述的杂环为饱和杂环或部分饱和杂环;所述的杂环为单环或螺环;G为N、C或CH;n为0或1;R 4独立地为C 1-6烷基、或、被一个或多个R 4-1取代的C 1-6烷基;R 4-1独立地为氰基、羟基或-C(=O)NR 4eR 4f;R 4e和R 4f独立地为氢或C 1-6烷基;R 2为CN、-C(=O)-C(R a)=C(R b)(R f)、-C(=O)-C≡C-Me或、-S(=O) 2-C(R a)=C(R b)(R f);R a独立地为氢或卤素;R b和R f独立地为氢、C 1-6烷基、C 1-6烷基-C(=O)-、或、被一个或多个R b-1取代的C 1-6烷基;R b-1独立地为卤素、羟基、C 1-6烷氧基、或、-NR 10jR 10k;R 10j和R 10k独立地为氢或C 1-6烷基,或者,R 10j、R 10k以及与之相连的N共同形成“含1-3个杂原子,杂原子为O和N中的一种或多种的4-6元杂环烷基”;方案7:R 1为C 6-20芳基、“含1-4个杂原子,杂原子为O、S和N中的一种或多种的5-12元杂芳基”、被一个或多个R 1-6取代的C 6-20芳基、或、被一个或多个R 1-7取代的“含1-4个杂原子,杂原子为O、S和N中的一种或多种的5-12元杂芳基”;R 1-6独立地为卤素、C 1-6烷基、或、被一个或多个R 1-6-1取代的C 1-6烷基;R 1-6-1独立地为卤素;m为0;R 3为-OR 31、-SR 32或-NR 33R 34;R 31、R 32和R 34独立地为被一个或多个R 31-1取代的C 1-6烷基;R 33独立地为H、C 1-6烷基或被一个或多个R 31-1取代的C 1-6烷基;R 31-1独立地为被一个或多个R d15取代的“含1-3个杂原子,杂原子为O和N中的一种或多种的5-7元杂环烷基”、或、-NR e1R e2;R d15独立地为C 1-6烷基或卤素;R e1和R e2独立地为C 1-6烷基;环Y为含1-4个N原子的4-12元杂环;所述的杂环为饱和杂环或部分饱和杂环;所述的杂环为单环;G为N;n为0或1;R 4独立地为被一个或多个R 4-1取代的C 1-6烷基;R 4-1独立地为氰基或-C(=O)NR 4eR 4f;R 4e和R 4f独立地为氢或C 1-6烷基;R 2为CN、-C(=O)-C(R a)=C(R b)(R f);R a独立地为氢或卤素;R b和R f独立地为氢、C 1-6烷基、或、C 1-6烷基-C(=O)-。
- 如权利要求1-6中任一项所述的如式I所示的含氧杂环化合物、其药学上可接受的盐、其溶剂合物、其药学上可接受的盐的溶剂合物、其晶型、其立体异构体、其互变异构体或其同位素化合物, 其特征在于,如式I所示的含氧杂环化合物的结构如下: 的混合物,它们的摩尔比例如1:1”;和/或,当所述的R 1为C 6-20芳基时,所述的C 6-20芳基为苯基或萘基;和/或,当所述的R 1为“含1-4个杂原子,杂原子为O、S和N中的一种或多种的5-12元杂芳基”时,所述的“含1-4个杂原子,杂原子为O、S和N中的一种或多种的5-12元杂芳基”为“含1-4个杂原子,杂原子为O、S和N中的一种或多种的9-10元杂芳基”;和/或,当所述的R 1为被一个或多个R 1-6取代的C 6-20芳基时,所述的C 6-20芳基为苯基或萘基;和/或,当所述的R 1为被一个或多个R 1-6取代的C 6-20芳基时,所述的多个为2个或3个;和/或,当所述的R 1-6独立地为卤素时,所述的卤素为氟、氯、溴或碘;和/或,当所述的R 1-6独立地为C 1-6烷基时,所述的C 1-6烷基为C 1-4烷基;和/或,当所述的R 1-6独立地为被一个或多个R 1-6-1取代的C 1-6烷基时,所述的C 1-6烷基为C 1-4烷基;和/或,当所述的R 1-6独立地为被一个或多个R 1-6-1取代的C 1-6烷基时,所述的多个为2个或3个;和/或,当所述的R 1-6-1独立地为卤素时,所述的卤素为氟、氯、溴或碘;和/或,当所述的R 31、R 33和R 34独立地为被一个或多个R 31-1取代的C 1-6烷基时,所述的C 1-6烷基为C 1-4烷基;和/或,当所述的R 31、R 33和R 34独立地为被一个或多个R 31-1取代的C 1-6烷基时,所述的多个为2个或3个;和/或,当所述的R 31-1独立地为被一个或多个R d15取代的“含1-3个杂原子,杂原子为O和N中的一种或多种的4-10元杂环烷基”时,所述的“含1-3个杂原子,杂原子为O和N中的一种或多种的4-10元杂环烷基”为“含1-3个杂原子,杂原子为O和N中的一种或多种的5-7元杂环烷基”;和/或,当所述的R 31-1独立地为被一个或多个R d15取代的“含1-3个杂原子,杂原子为O和N中的一种或多种的4-10元杂环烷基”时,所述的多个为2个或3个;和/或,当所述的R d15独立地为C 1-6烷基时,所述的C 1-6烷基为C 1-4烷基;和/或,当所述的R d15独立地为卤素时,所述的卤素为氟、氯、溴或碘;和/或,当所述的R e1和R e2独立地为C 1-6烷基时,所述的C 1-6烷基为C 1-4烷基;和/或,当所述的环Y为含1-4个N原子的4-12元杂环时,所述的含1-4个N原子的4-12元杂环为含1-2个N原子的6-9元杂环;和/或,当所述的R 4独立地为C 1-6烷基时,所述的C 1-6烷基为C 1-4烷基;和/或,当所述的R 4独立地为被一个或多个R 4-1取代的C 1-6烷基时,所述的C 1-6烷基为C 1-4烷基;和/或,当所述的R 4独立地为被一个或多个R 4-1取代的C 1-6烷基时,所述的多个为2个或3个;和/或,当所述的R a独立地为卤素时,所述的卤素为氟、氯、溴或碘;和/或,当所述的R b和R f独立地为C 1-6烷基时,所述的C 1-6烷基为C 1-4烷基;和/或,当所述的R b和R f独立地为被一个或多个R b-1取代的C 1-6烷基时,所述的C 1-6烷基为C 1-4烷基;和/或,当所述的R b和R f独立地为被一个或多个R b-1取代的C 1-6烷基时,所述的多个为2个或3个;和/或,当所述的R 10j和R 10k独立地为C 1-6烷基时,所述的C 1-6烷基为C 1-4烷基。
- 如权利要求7所述的如式I所示的含氧杂环化合物、其药学上可接受的盐、其溶剂合物、其药学上可接受的盐的溶剂合物、其晶型、其立体异构体、其互变异构体或其同位素化合物,其特征在于,当所述的R 1为“含1-4个杂原子,杂原子为O、S和N中的一种或多种的5-12元杂芳基”时,所述的“含1-4个杂原子,杂原子为O、S和N中的一种或多种的5-12元杂芳基”为异喹啉基;和/或,当所述的R 1为被一个或多个R 1-6取代的C 6-20芳基时,所述的C 6-20芳基为苯基或1-萘基;和/或,当所述的R 1-6独立地为卤素时,所述的卤素为氟或氯;和/或,当所述的R 1-6独立地为C 1-6烷基时,所述的C 1-6烷基为甲基、乙基、正丙基、异丙基、正丁基、异丁基、仲丁基或叔丁基;和/或,当所述的R 1-6独立地为被一个或多个R 1-6-1取代的C 1-6烷基时,所述的C 1-6烷基为甲基、乙基、正丙基、异丙基、正丁基、异丁基、仲丁基或叔丁基;和/或,当所述的R 1-6-1独立地为卤素时,所述的卤素为氟;和/或,当所述的R 31、R 33和R 34独立地为被一个或多个R 31-1取代的C 1-6烷基时,所述的C 1-6烷基为甲基、乙基、正丙基、异丙基、正丁基、异丁基、仲丁基或叔丁基;和/或,当所述的R 31-1独立地为被一个或多个R d15取代的“含1-3个杂原子,杂原子为O和N中的一种或多种的4-10元杂环烷基”时,所述的“含1-3个杂原子,杂原子为O和N中的一种或多种的4-10元杂环烷基”为“含1个杂原子,杂原子为O和N中的一种的5-7元杂环烷基”;和/或,当所述的R d15独立地为C 1-6烷基时,所述的C 1-6烷基为甲基、乙基、正丙基、异丙基、正丁基、异丁基、仲丁基或叔丁基;和/或,当所述的R d15独立地为卤素时,所述的卤素为氟;和/或,当所述的R e1和R e2独立地为C 1-6烷基时,所述的C 1-6烷基为甲基、乙基、正丙基、异丙基、正丁基、异丁基、仲丁基或叔丁基;和/或,当所述的R 4独立地为C 1-6烷基时,所述的C 1-6烷基为甲基、乙基、正丙基、异丙基、正丁基、异丁基、仲丁基或叔丁基;和/或,当所述的R 4独立地为被一个或多个R 4-1取代的C 1-6烷基时,所述的C 1-6烷基为甲基、乙基、正丙基、异丙基、正丁基、异丁基、仲丁基或叔丁基;和/或,当所述的R a独立地为卤素时,所述的卤素为氟;和/或,当所述的R b和R f独立地为C 1-6烷基时,所述的C 1-6烷基为甲基、乙基、正丙基、异丙基、正丁基、异丁基、仲丁基或叔丁基;和/或,当所述的R b和R f独立地为被一个或多个R b-1取代的C 1-6烷基时,所述的C 1-6烷基为甲基、乙基、正丙基、异丙基、正丁基、异丁基、仲丁基或叔丁基;和/或,当所述的R 10j和R 10k独立地为C 1-6烷基时,所述的C 1-6烷基为甲基、乙基、正丙基、异丙基、正丁基、异丁基、仲丁基或叔丁基。
- 如权利要求8所述的如式I所示的含氧杂环化合物、其药学上可接受的盐、其溶剂合物、其药学上可接受的盐的溶剂合物、其晶型、其立体异构体、其互变异构体或其同位素化合物,其特征在于,当所述的R 1为“含1-4个杂原子,杂原子为O、S和N中的一种或多种的5-12元杂芳基”时,所述的“含1-4个杂原子,杂原子为O、S和N中的一种或多种的5-12元杂芳基”为和/或,当所述的R 1-6独立地为C 1-6烷基时,所述的C 1-6烷基为甲基;和/或,当所述的R 1-6独立地为被一个或多个R 1-6-1取代的C 1-6烷基时,所述的被一个或多个R 1-6- 1取代的C 1-6烷基为三氟甲基;和/或,当所述的R 31、R 33和R 34独立地为被一个或多个R 31-1取代的C 1-6烷基时,所述的C 1-6烷基为甲基、乙基、正丙基或异丙基;和/或,当所述的R 31-1独立地为被一个或多个R d15取代的“含1-3个杂原子,杂原子为O和N中的一种或多种的4-10元杂环烷基”时,所述的“含1-3个杂原子,杂原子为O和N中的一种或多种的4-10元杂环烷基”为四氢吡咯基;和/或,当所述的R d15独立地为C 1-6烷基时,所述的C 1-6烷基为甲基;和/或,当所述的R e1和R e2独立地为C 1-6烷基时,所述的C 1-6烷基为甲基或乙基;和/或,当所述的R 4独立地为C 1-6烷基时,所述的C 1-6烷基为甲基;和/或,当所述的R 4独立地为被一个或多个R 4-1取代的C 1-6烷基时,所述的C 1-6烷基为甲基;和/或,当所述的R b和R f独立地为C 1-6烷基时,所述的C 1-6烷基为甲基;和/或,当所述的R b和R f独立地为被一个或多个R b-1取代的C 1-6烷基时,所述的C 1-6烷基为甲基;和/或,当所述的R 10j和R 10k独立地为C 1-6烷基时,所述的C 1-6烷基为甲基。
- 如权利要求9所述的如式I所示的含氧杂环化合物、其药学上可接受的盐、其溶剂合物、其药学上可接受的盐的溶剂合物、其晶型、其立体异构体、其互变异构体或其同位素化合物,其特征在于,和/或,当所述的R 33独立地为C 1-6烷基时,所述的C 1-6烷基为甲基、乙基、正丙基、异丙基、正丁基、异丁基、仲丁基或叔丁基,还可为甲基、乙基、正丙基或异丙基;和/或,当所述的R b和R f独立地为C 1-6烷基-C(=O)-时,所述的C 1-6烷基-C(=O)-里的C 1-6烷基为甲基、乙基、正丙基、异丙基、正丁基、异丁基、仲丁基或叔丁基,还可为甲基;
- 如权利要求9所述的如式I所示的含氧杂环化合物、其药学上可接受的盐、其溶剂合物、其药 学上可接受的盐的溶剂合物、其晶型、其立体异构体、其互变异构体或其同位素化合物,其特征在于,和/或,当所述的R 4独立地为被一个或多个R 4-1取代的C 1-6烷基时,所述的被一个或多个R 4-1取代的C 1-6烷基为羟基甲基或氰基甲基;和/或,当所述的R 10j和R 10k以及与之相连的N共同形成“含1-3个杂原子,杂原子为O和N中的一种或多种的4-10元杂环烷基”时,所述的“含1-3个杂原子,杂原子为O和N中的一种或多种的4-10元杂环烷基”为“含2个杂原子,杂原子为O和N的5-6元杂环烷基”,又可为
- 如权利要求9所述的如式I所示的含氧杂环化合物、其药学上可接受的盐、其溶剂合物、其药学上可接受的盐的溶剂合物、其晶型、其立体异构体、其互变异构体或其同位素化合物,其特征在于,当所述的R 1为被一个或多个R 1-6取代的C 6-20芳基时,所述的被一个或多个R 1-6取代的C 6-20芳基为和/或,当所述的R 4独立地为被一个或多个R 4-1取代的C 1-6烷基时,所述的被一个或多个R 4-1取代的C 1-6烷基为氰基甲基;
- 如权利要求1所述的如式I所示的含氧杂环化合物、其药学上可接受的盐、其溶剂合物、其药学上可接受的盐的溶剂合物、其晶型、其立体异构体、其互变异构体或其同位素化合物,其特征在于,所述的如式I所示的含氧杂环化合物为如下任一化合物:在下述条件下保留时间为0.92min的化合物 设备:SFC Method Station(Thar,Waters);色谱柱:OD-H 4.6*100mm,5μm(Daicel);柱温:40℃;流动相:CO 2/MeOH(0.1%TEA)=65/35;流速:4.0ml/min;波长:254nm;背压:120bar;在下述条件下保留时间为2.74min的化合物 设备:SFC Method Station(Thar,Waters);色谱柱:OD-H 4.6*100mm,5μm(Daicel);柱温:40℃;流动相:CO 2/MeOH(0.1%TEA)=65/35;流速:4.0ml/min;波长:254nm;背压:120bar;在下述条件下保留时间为0.97min的化合物 设备:SFC Method Station(Thar,Waters);色谱柱:AD-H 4.6*100mm,5μm(Daicel);柱温:40℃;流动相:CO 2/ETOH(0.5%TEA)=55/45;流速:4.0ml/min;波长:254nm;背压:120bar;在下述条件下保留时间为2.40min的化合物 设备:SFC Method Station(Thar,Waters);色谱柱:AD-H 4.6*100mm,5μm(Daicel);柱温:40℃;流动相:CO 2/ETOH(0.5%TEA)=55/45;流速:4.0ml/min;波长:254nm;背压:120bar;在下述条件下保留时间为0.97min的化合物: 设备:SFC Method Station (Thar,Waters);色谱柱:OJ-H 4.6*100mm,5μm(Daicel);柱温:40℃;流动相:CO 2/Methanol(0.1%TEA)=60/40;流速:4.0ml/min;波长:254nm;背压:120bar;在下述条件下保留时间为1.94min的化合物 设备:SFC Method Station(Thar,Waters);色谱柱:OJ-H 4.6*100mm,5μm(Daicel);柱温:40℃;流动相:CO 2/Methanol(0.1%TEA)=60/40;流速:4.0ml/min;波长:254nm;背压:120bar;在下述条件下保留时间为1.22min的化合物 设备:SFC Method Station(Thar,Waters);色谱柱:CHIRALCEL OJ-H 4.6*100mm,5μm(Daicel);柱温:40℃;流动相:CO 2/MeOH(0.1%TEA)=65/35;流速:1.0ml/min;波长:214nm;背压:120bar;在下述条件下保留时间为2.67min的化合物 设备:SFC Method Station(Thar,Waters);色谱柱:CHIRALCEL OJ-H 4.6*100mm,5μm(Daicel);柱温:40℃;流动相:CO 2/MeOH(0.1%TEA)=65/35;流速:1.0ml/min;波长:214nm;背压:120bar;在下述条件下保留时间为3.26min的化合物 仪器:SFC Method Station(Thar,Waters);色谱柱:R,R-WHELK-O1 4.6*100mm,5μm(REGIS);柱温:40℃;流动相:CO2/(MeOH/ACN=3:2(0.1%TEA))=55/45;流速:4.0ml/min;波长:254nm;背压:120bar;在下述条件下保留时间为4.16min的化合物 仪器:SFC Method Station(Thar,Waters);色谱柱:R,R-WHELK-O1 4.6*100mm,5μm(REGIS);柱温:40℃;流动相:CO 2/(MeOH/ACN=3:2(0.1%TEA))=55/45;流速:4.0ml/min;波长:254nm;背压:120bar;在下述条件下保留时间为1.36min的化合物 仪器:SFC Method Station(Thar,Waters);色谱柱:OJ-H 4.6*100mm,5μm(Daicel);柱温:40℃;流动相:CO 2/MeOH(0.1%TEA)=60/40;流速:4.0ml/min;波长:254nm;背压:120bar;在下述条件下保留时间为2.77min的化合物 仪器:SFC Method Station(Thar,Waters);色谱柱:OJ-H 4.6*100mm,5μm(Daicel);柱温:40℃;流动相:CO 2/MeOH(0.1%TEA)=60/40;流速:4.0ml/min;波长:254nm;背压:120bar;在下述条件下保留时间为1.17min的化合物 仪器:SFC Method Station(Thar,Waters);色谱柱:OJ-H 4.6*100mm,5μm(Daicel);柱温:40℃;流动相:CO 2/MeOH(0.1%TEA)=60/40;流速:4.0ml/min;波长:254nm;背压:120bar;在下述条件下保留时间为2.76min的化合物 仪器:SFC Method Station(Thar,Waters);色谱柱:OJ-H 4.6*100mm,5μm(Daicel);柱温:40℃;流动相:CO 2/MeOH(0.1%TEA)=60/40;流速:4.0ml/min;波长:254nm;背压:120bar;在下述条件下保留时间为0.78min的化合物 仪器:SFC Method Station(Thar,Waters);色谱柱:AD-H 4.6*100mm,5μm(Daicel);柱温:40℃;流动相:CO 2/MeOH(0.1%TEA)=65/35;流速:4.0ml/min;波长:254nm;背压:120bar;在下述条件下保留时间为2.42min的化合物 仪器:SFC Method Station(Thar,Waters);色谱柱:AD-H 4.6*100mm,5μm(Daicel);柱温:40℃;流动相:CO 2/MeOH(0.1%TEA)=65/35;流速:4.0ml/min;波长:254nm;背压:120bar;在下述条件下保留时间为0.79min的化合物 仪器:SFC Method Station(Thar,Waters);色谱柱:OD-H 4.6*100mm,5μm(Daicel);柱温:40℃;流动相:CO 2/MeOH(0.1%TEA)=65/35;流速:4.0ml/min;波长:254nm;背压:120bar;在下述条件下保留时间为2.29min的化合物 仪器:SFC Method Station(Thar,Waters);色谱柱:OD-H 4.6*100mm,5μm(Daicel);柱温:40℃;流动相:CO 2/MeOH(0.1%TEA)=65/35;流速:4.0ml/min;波长:254nm;背压:120bar;在下述条件下保留时间为1.45min的化合物 仪器:SFC Method Station(Thar,Waters);色谱柱:OJ-H 4.6*100mm,5μm(Daicel);柱温:40℃;流动相:CO 2/MeOH(0.1%TEA)=60/40;流速:4.0ml/min;波长:254nm;背压:120bar;
- 一种药物组合物,其包含物质A和药用辅料;所述的物质A为如权利要求1-15中任一项所述的如式I所示的含氧杂环化合物、其药学上可接受的盐、其溶剂合物、其药学上可接受的盐的溶剂合物、其晶型、其立体异构体、其互变异构体或其同位素化合物。
- 一种物质A在制备RAS抑制剂或者药物中的应用,所述的物质A为如权利要求1-15中任一项所述的如式I所示的含氧杂环化合物、其药学上可接受的盐、其溶剂合物、其药学上可接受的盐的溶剂合物、其晶型、其立体异构体、其互变异构体或其同位素化合物;所述的药物用于治疗或预防RAS介导的疾病;或者,所述的药物用于治疗或预防癌症;所述的RAS介导的疾病例如癌症;所述的癌症例如结肠癌、胰腺癌、乳腺癌、前列腺癌、肺癌、脑癌、卵巢癌、子宫颈癌、睾丸癌、肾癌、头或颈癌、骨癌、皮肤癌、直肠癌、肝癌、结肠癌、食道癌、胃癌、胰腺癌、甲状腺癌、膀胱癌、淋巴瘤、白血病和黑色素瘤中的一种或多种。
- 一种抑制RAS、或治疗或预防RAS介导的疾病、或治疗或预防癌症的方法,其包括向患者 施用治疗有效量的物质A;所述的物质A为如权利要求1-15中任一项所述的如式I所示的含氧杂环化合物、其药学上可接受的盐、其溶剂合物、其药学上可接受的盐的溶剂合物、其晶型、其立体异构体、其互变异构体或其同位素化合物;所述的RAS介导的疾病例如癌症;所述的癌症例如结肠癌、胰腺癌、乳腺癌、前列腺癌、肺癌、脑癌、卵巢癌、子宫颈癌、睾丸癌、肾癌、头或颈癌、骨癌、皮肤癌、直肠癌、肝癌、结肠癌、食道癌、胃癌、胰腺癌、甲状腺癌、膀胱癌、淋巴瘤、白血病和黑色素瘤中的一种或多种。
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020227022934A KR20220136349A (ko) | 2019-12-02 | 2020-10-21 | 산소 함유 헤테로고리 화합물, 그의 제조 방법 및 응용 |
US17/767,046 US20220315598A1 (en) | 2019-12-02 | 2020-10-21 | Oxygen-containing Heterocyclic Compound, Preparation Method Therefor and Use Thereof |
JP2022532809A JP2023504178A (ja) | 2019-12-02 | 2020-10-21 | 酸素含有複素環化合物、その製造方法及び使用 |
AU2020395397A AU2020395397A1 (en) | 2019-12-02 | 2020-10-21 | Oxygen-containing heterocyclic compound, preparation method and application thereof |
CA3163218A CA3163218A1 (en) | 2019-12-02 | 2020-10-21 | Oxygen-containing heterocyclic compound, preparation method therefor and use thereof |
MX2022006663A MX2022006663A (es) | 2019-12-02 | 2020-10-21 | Compuesto heterociclico que contiene oxigeno, metodo de preparacion de este y uso de este. |
EP20895574.0A EP4015520A4 (en) | 2019-12-02 | 2020-10-21 | HETEROCYCLIC COMPOUND CONTAINING OXYGEN, METHOD FOR PREPARING IT AND ITS USE |
BR112022010254A BR112022010254A2 (pt) | 2019-12-02 | 2020-10-21 | Composto heterocíclico contendo oxigênio representado pela fórmula i, método para preparar o composto heterocíclico contendo oxigênio, composto, composição farmacêutica e uso composto heterocíclico contendo oxigênio |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911212840.3 | 2019-12-02 | ||
CN201911212840 | 2019-12-02 | ||
CN202010368798.0 | 2020-04-29 | ||
CN202010368798 | 2020-04-29 | ||
CN202011077052.0 | 2020-10-10 | ||
CN202011077052.0A CN112979664B (zh) | 2019-12-02 | 2020-10-10 | 一种含氧杂环化合物、其制备方法及应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021109737A1 true WO2021109737A1 (zh) | 2021-06-10 |
Family
ID=76221416
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2020/122335 WO2021109737A1 (zh) | 2019-12-02 | 2020-10-21 | 一种含氧杂环化合物、其制备方法及应用 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20220315598A1 (zh) |
EP (1) | EP4015520A4 (zh) |
JP (1) | JP2023504178A (zh) |
KR (1) | KR20220136349A (zh) |
AU (1) | AU2020395397A1 (zh) |
BR (1) | BR112022010254A2 (zh) |
CA (1) | CA3163218A1 (zh) |
MX (1) | MX2022006663A (zh) |
WO (1) | WO2021109737A1 (zh) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220112204A1 (en) * | 2020-10-14 | 2022-04-14 | Accutar Biotechnology Inc. | Substituted dihydropyranopyrimidine compounds as kras inhibitors |
WO2022187527A1 (en) * | 2021-03-05 | 2022-09-09 | Nikang Therapeutics, Inc | Quinazoline nitrile derivatives as kras inhibitors |
US11453683B1 (en) | 2019-08-29 | 2022-09-27 | Mirati Therapeutics, Inc. | KRas G12D inhibitors |
WO2022247772A1 (zh) * | 2021-05-24 | 2022-12-01 | 上海璎黎药业有限公司 | 一种含氧杂环化合物的晶型、其制备方法及应用 |
US11548888B2 (en) | 2019-01-10 | 2023-01-10 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
WO2023008462A1 (ja) | 2021-07-27 | 2023-02-02 | 東レ株式会社 | 癌の治療及び/又は予防のための医薬品 |
US11697657B2 (en) | 2019-10-28 | 2023-07-11 | Merck Sharp & Dohme Llc | Small molecule inhibitors of KRAS G12C mutant |
US11702418B2 (en) | 2019-12-20 | 2023-07-18 | Mirati Therapeutics, Inc. | SOS1 inhibitors |
WO2023205074A1 (en) * | 2022-04-18 | 2023-10-26 | Mirati Therapeutics, Inc. | Processes and intermediates for synthesis of adagrasib |
US11890285B2 (en) | 2019-09-24 | 2024-02-06 | Mirati Therapeutics, Inc. | Combination therapies |
US11932633B2 (en) | 2018-05-07 | 2024-03-19 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
US11964989B2 (en) | 2022-07-20 | 2024-04-23 | Mirati Therapeutics, Inc. | KRas G12D inhibitors |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010064705A1 (ja) * | 2008-12-05 | 2010-06-10 | 大日本住友製薬株式会社 | H4受容体アンタゴニスト作用を有する新規7位置換ジヒドロピラノピリミジン誘導体 |
CN102480961A (zh) * | 2009-06-24 | 2012-05-30 | 健泰科生物技术公司 | 与含氧杂环稠合的嘧啶化合物、组合物和使用方法 |
CN108473504A (zh) * | 2015-12-08 | 2018-08-31 | St制药株式会社 | 新型二氢吡喃并嘧啶酮衍生物及其用途 |
CN109843856A (zh) * | 2016-05-18 | 2019-06-04 | 米拉蒂治疗股份有限公司 | Kras g12c抑制剂 |
US20190248767A1 (en) * | 2018-02-09 | 2019-08-15 | Pfizer Inc. | Tetrahydroquinazoline Derivatives Useful as Anticancer Agents |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA125802C2 (uk) * | 2017-11-15 | 2022-06-08 | Міраті Терапьютікс, Інк. | Інгібітори kras g12c |
WO2021106231A1 (en) * | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
MX2022011283A (es) * | 2020-03-12 | 2022-11-16 | D3 Bio Wuxi Co Ltd | Compuestos pirimidoheterocíclicos y aplicación de los mismos. |
-
2020
- 2020-10-21 AU AU2020395397A patent/AU2020395397A1/en active Pending
- 2020-10-21 US US17/767,046 patent/US20220315598A1/en active Pending
- 2020-10-21 WO PCT/CN2020/122335 patent/WO2021109737A1/zh unknown
- 2020-10-21 KR KR1020227022934A patent/KR20220136349A/ko unknown
- 2020-10-21 CA CA3163218A patent/CA3163218A1/en active Pending
- 2020-10-21 EP EP20895574.0A patent/EP4015520A4/en active Pending
- 2020-10-21 JP JP2022532809A patent/JP2023504178A/ja active Pending
- 2020-10-21 BR BR112022010254A patent/BR112022010254A2/pt unknown
- 2020-10-21 MX MX2022006663A patent/MX2022006663A/es unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010064705A1 (ja) * | 2008-12-05 | 2010-06-10 | 大日本住友製薬株式会社 | H4受容体アンタゴニスト作用を有する新規7位置換ジヒドロピラノピリミジン誘導体 |
CN102480961A (zh) * | 2009-06-24 | 2012-05-30 | 健泰科生物技术公司 | 与含氧杂环稠合的嘧啶化合物、组合物和使用方法 |
CN108473504A (zh) * | 2015-12-08 | 2018-08-31 | St制药株式会社 | 新型二氢吡喃并嘧啶酮衍生物及其用途 |
CN109843856A (zh) * | 2016-05-18 | 2019-06-04 | 米拉蒂治疗股份有限公司 | Kras g12c抑制剂 |
US20190248767A1 (en) * | 2018-02-09 | 2019-08-15 | Pfizer Inc. | Tetrahydroquinazoline Derivatives Useful as Anticancer Agents |
WO2019155399A1 (en) | 2018-02-09 | 2019-08-15 | Pfizer Inc. | Tetrahydroquinazoline derivatives useful as anticancer agents |
Non-Patent Citations (8)
Title |
---|
"Encyclopedia of Reagents for Organic Synthesis", 1995, JOHN WILEY AND SONS |
"Handbook of Pharmaceutical Salts: Properties, Selection, and Use", 2002, WILEY-VCH |
BERGE ET AL.: "Pharmaceutical Salts", JOURNAL OF PHARMACEUTICAL SCIENCE, vol. 66, 1977, pages 1 - 19, XP002675560, DOI: 10.1002/jps.2600660104 |
L. FIESERM. FIESER: "Fieser and Fieser's Reagents for Organic Synthesis", 1994, JOHN WILEY AND SONS |
NATURE, vol. 503, 2013, pages 548 - 551 |
R. LAROCK: "Comprehensive Organic Transformations", 1989, VCH PUBLISHERS |
SCIENCE, vol. 351, 2016, pages 604 - 608 |
T. W. GREENEP. G. M. WUTS: "Protective Groups in Organic Synthesis", 1999, JOHN WILEY AND SONS |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11932633B2 (en) | 2018-05-07 | 2024-03-19 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
US11548888B2 (en) | 2019-01-10 | 2023-01-10 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
US11453683B1 (en) | 2019-08-29 | 2022-09-27 | Mirati Therapeutics, Inc. | KRas G12D inhibitors |
US11890285B2 (en) | 2019-09-24 | 2024-02-06 | Mirati Therapeutics, Inc. | Combination therapies |
US11697657B2 (en) | 2019-10-28 | 2023-07-11 | Merck Sharp & Dohme Llc | Small molecule inhibitors of KRAS G12C mutant |
US11702418B2 (en) | 2019-12-20 | 2023-07-18 | Mirati Therapeutics, Inc. | SOS1 inhibitors |
WO2022081655A1 (en) * | 2020-10-14 | 2022-04-21 | Accutar Biotechnology, Inc. | Substituted dihydropyranopyrimidine compounds as kras inhibitors |
US20220112204A1 (en) * | 2020-10-14 | 2022-04-14 | Accutar Biotechnology Inc. | Substituted dihydropyranopyrimidine compounds as kras inhibitors |
WO2022187527A1 (en) * | 2021-03-05 | 2022-09-09 | Nikang Therapeutics, Inc | Quinazoline nitrile derivatives as kras inhibitors |
WO2022247772A1 (zh) * | 2021-05-24 | 2022-12-01 | 上海璎黎药业有限公司 | 一种含氧杂环化合物的晶型、其制备方法及应用 |
WO2023008462A1 (ja) | 2021-07-27 | 2023-02-02 | 東レ株式会社 | 癌の治療及び/又は予防のための医薬品 |
WO2023205074A1 (en) * | 2022-04-18 | 2023-10-26 | Mirati Therapeutics, Inc. | Processes and intermediates for synthesis of adagrasib |
US11964989B2 (en) | 2022-07-20 | 2024-04-23 | Mirati Therapeutics, Inc. | KRas G12D inhibitors |
Also Published As
Publication number | Publication date |
---|---|
AU2020395397A1 (en) | 2022-06-09 |
KR20220136349A (ko) | 2022-10-07 |
JP2023504178A (ja) | 2023-02-01 |
MX2022006663A (es) | 2022-07-05 |
EP4015520A1 (en) | 2022-06-22 |
US20220315598A1 (en) | 2022-10-06 |
CA3163218A1 (en) | 2021-06-10 |
BR112022010254A2 (pt) | 2022-09-06 |
EP4015520A4 (en) | 2023-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021109737A1 (zh) | 一种含氧杂环化合物、其制备方法及应用 | |
TWI730937B (zh) | Gpr6 的四氫吡啶並吡調節劑 | |
EP3580224B1 (en) | Ask1 inhibiting agents | |
CN103153954B (zh) | N-酰基磺酰胺凋亡促进剂 | |
TWI626050B (zh) | 吡唑並[1,5-a]嘧啶類之醫藥組成物與用途 | |
CN106687446B (zh) | 作为t790m/wt-egfr的选择性和不可逆的激酶抑制剂的5-氨基-4-氨甲酰基-吡唑化合物及其用途 | |
CN108699032A (zh) | 多环tlr7/8拮抗剂及其在治疗免疫失调中的用途 | |
CN107106559A (zh) | 自分泌运动因子的取代的螺环抑制剂 | |
CN102712640A (zh) | 三环杂环化合物、其组合物和应用方法 | |
CN112979664A (zh) | 一种含氧杂环化合物、其制备方法及应用 | |
CN105793238A (zh) | 经取代的苯甲酰胺及其使用方法 | |
BR122020003153B1 (pt) | Processos para fabricação e formas cristalinas de um inibidor de mdm2 | |
AU2019334065A1 (en) | Tricyclic compounds acting on CRBN proteins | |
WO2021043322A1 (zh) | 氮杂环庚烷并嘧啶类衍生物及其医药用途 | |
CN104039789B (zh) | 四氮杂-环戊二烯并[a]茚基及其作为正向变构调节剂的用途 | |
WO2019037761A1 (zh) | 含有氨基吡唑并嘧啶的大环化合物及其药物组合物和用途 | |
JP2022506399A (ja) | ヒト免疫不全ウイルス複製の阻害剤 | |
CN114230512A (zh) | 芳香乙烯类化合物、其制备方法、中间体、药物组合物及其应用 | |
CN113950477A (zh) | 颗粒体蛋白前体调节剂和其使用方法 | |
EP3083624B1 (en) | Tetrahydro-tetrazolo[1,5-a]pyrazines as ror-gamma inhibitors | |
JP2022505637A (ja) | ヒト免疫不全ウイルス複製の阻害剤 | |
CN114007695A (zh) | 作为am2受体抑制剂的杂环螺-化合物 | |
CN115385936A (zh) | 一种含氮杂环化合物、其制备方法及应用 | |
TWI810547B (zh) | Pd-l1拮抗劑化合物 | |
WO2023143352A1 (zh) | 一种含氮杂环化合物、其制备方法及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20895574 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2020895574 Country of ref document: EP Effective date: 20220314 |
|
ENP | Entry into the national phase |
Ref document number: 3163218 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2022532809 Country of ref document: JP Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112022010254 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2020395397 Country of ref document: AU Date of ref document: 20201021 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 112022010254 Country of ref document: BR Kind code of ref document: A2 Effective date: 20220526 |